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ABSTRACT 
Jeffrey Jon Olney:  An Examination of the Role of the Central Orexin System in Binge-Like 
Ethanol Consumption 
(Under the direction of Todd Thiele) 
Although centrally synthesized exclusively within the hypothalamus, orexin (OX) 
neurons project to various structures throughout the brain to modulate a host of physiological 
functions, including reward processing and stress responding, each of which contributes to the 
likelihood that an individual may drink ethanol.  More recent evidence has also implicated this 
system in modulating the neurobiological responses to ethanol.  The goal of the present 
dissertation was to further examine the role of the OX system in neurobiological responses to 
ethanol by characterizing the participation of this peptide system in binge-like ethanol drinking 
behavior.  We assessed the impact of repeated episodes of binge-like ethanol drinking on 
different aspects of the OX system in Chapter 2 and found that binge-like ethanol drinking 
caused evidence of increased OX signaling, particularly within the lateral hypothalamus (LH), 
but did not produce lasting changes in mRNA expression.  In Chapter 3, we used site-directed 
pharmacological tools to examine the individual contribution of each OX receptor, the OX1R 
and OX2R, within the ventral tegmental area (VTA) in binge-like ethanol drinking.  Here, we 
observed that signaling onto the OX1R, but not OX2R, selectively modulates binge-like ethanol 
drinking without affecting sucrose consumption.  Moreover, further investigations revealed that 
it does so independent of stress modulation as inhibiting intra-VTA OX1Rs did not alter anxiety-
like behavior.  Similarly, Chapter 4 was designed to characterize the participation of each OXR 
within the central nucleus of the amygdala (CeA).  Using selective antagonists directly infused 
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into the CeA, we found that binge-like ethanol drinking within this region is predominately 
regulated by the OX1R and that this circuitry is independent of that which modulates responding 
to natural reinforcers and stress as inhibiting OX1Rs within the CeA did not affect binge-like 
sucrose consumption nor did it alter anxiety-like behavior.  Together, these data indicate that the 
OX system significantly contributes to binge-like ethanol drinking and reveal that the LHVTA 
and LHCeA are two key pathways that selectively modulate this behavior.  More broadly, 
these findings implicate the OX system as a highly promising target for the treatment of alcohol 
use disorders. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Ethanol is produced via the biochemical process of fermentation when yeast metabolizes 
sugars (e.g. glucose:  C6H12O6) into ethanol and carbon dioxide (C2H5OH + CO2).  Early humans 
took advantage of this process to produce alcoholic beverages; in fact, it is believed that the 
earliest iteration was most likely mead, which is made from fermented honey, and is estimated to 
have emerged during the Paleolithic Age (8000 BCE;  Ray and Ksir, 2002).  Since then, alcohol 
has been a major part of human society and was even found referenced in Hammurabi’s code 
(1720 BCE), which included a mandate to set the price and quality of beer (Mandelbaum, 1965).  
In fact, alcohol, having approximately 7 kcal per gram (The National Agricultural Library, 
2015), was a major component of a nutrient-rich diet at the time (Homan, 2004).  Additionally, 
the fermentation process eliminates most harmful bacteria present in the water supply 
(Vriesekoop et al, 2012) and was considered a source of sanitary hydration (Homan, 2004).  For 
these reasons, early settlers of colonial America referred to alcohol as the “Good Creature of 
God,” yet they were able to differentiate between drinking for hydration and nutrients versus 
drinking for intoxication- considering the latter to be a sinful act (Acker and Tracy, 2004).   
This disdain for alcoholic inebriation would drive much of the public’s opinion of alcohol 
consumption over the next several centuries.  This attitude would reach fever pitch in the early 
20
th 
century and ultimately resulted in the 18
th
 Amendment to the U.S. Constitution, which 
banned the production, storage, and consumption of alcoholic beverages.  Interestingly, although 
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alcohol consumption dropped precipitously during the years of Prohibition (1919-1933), 
consumption was not fully eradicated (Nephew et al, 1999)- indicating that a portion of the 
American population opposed the enactment and chose to continue drinking despite the ban.  
Over the fourteen years of Prohibition, popular opinion steadily shifted and drinking rates 
continued to climb until the 21
st
 Amendment overturned Prohibition (Levine, 1984; Nephew et 
al, 1999).   Since then, alcohol has remained a mainstay of American culture.  In fact, Americans 
spend over $100 billion each year purchasing alcoholic beverages (Levine, 1984), but the health 
and socioeconomic cost of alcohol use far exceeds the monetary value generated from its sales.  
Alcohol Use and Abuse 
Alcohol abuse can lead to a host of harmful health conditions (Castaneda et al, 1996; 
Rehm et al, 2003; Sanap and Chapman, 2003; Smith et al, 1999) and remains the third leading 
cause of preventable death in the United States (Mokdad et al, 2004)- claiming an estimated 
90,000 lives each year (Naimi et al, 2003).  In addition to adverse health consequences, alcohol 
is also associated with high economic costs.  Indeed, the loss of work productivity, healthcare 
expenditures, and strain on the criminal justice system- among others- due to alcohol abuse has 
been estimated to cost nearly $250 billion (Sacks et al, 2015).  These costs are likely driven by 
the widespread use of alcohol as epidemiological surveys have found that the vast majority 
(nearly 88%) of American adults have reported consuming alcohol at least once in their lifetime 
while 71% had reported drinking during the past year and nearly half the past month (SAMHSA, 
2014).  Moreover, it has been estimated that over 17 million Americans currently meet the 
criteria for at least one alcohol use disorder (AUD; SAMHSA 2012).  In fact, the sheer 
magnitude of alcohol consumption is best illustrated by the fact that some investigators have 
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chosen to express the units of annual per-capita alcohol consumption in gallons (Nephew et al, 
1999; U.S. Census Bureau, 2012). 
Binge Alcohol Drinking 
One of the major factors that contributes to the large volume of alcohol consumption and 
high prevalence of AUDs is binge alcohol drinking, which has recently been defined by the 
National Institute on Alcohol Abuse and Alcoholism as the consumption of enough alcohol over 
a short period to achieve a blood ethanol concentration (BEC) of at least 80 mg/dl (NIAAA 
Newsletter, 2004).  In fact, of the nearly $250 billion annual cost attributed to alcohol abuse 
referenced above, a staggering $191.1 billion (76%) of that total is due to binge alcohol drinking 
(Sacks et al, 2015).  Although young adults make up a significant proportion of individuals who 
engage in binge drinking, approximately 70% of binge drinking episodes involve adults over the 
age of 26 (Naimi et al, 2003).  Indeed, nearly 25% of adults surveyed have reported to have 
recently engaged in binge drinking (SAMHSA, 2014).  Moreover, binge drinking is an activity 
adults frequently partake in as one in six report binge drinking about four times each month 
(CDC, 2010).  In fact, 75% of all alcohol consumed in the United States is done so in the form of 
a binge (OJJDP, 2005).  This is particularly problematic as frequent binge drinking may lead to 
alcohol dependence and abuse (Knight et al, 2002; Rubinsky et al, 2010).  Considering that 
approximately 1.5 million adults received treatment for an AUD in 2014 (SAMHSA, 2014), a 
better understanding of the neurobiological mechanisms that contribute to this harmful and costly 
disorder may be beneficial in facilitating the development of novel treatments for AUD’s. 
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Psychological Processes that Drive Alcohol Use and Abuse 
Despite the economic cost and adverse consequences to an individual’s welfare, people 
are nonetheless driven to drink alcohol.  Indeed, alcohol consumption is a complex human 
behavior; as such, the factors that motivate an individual to use or abuse alcohol are varied.  It is 
known that social factors may play a part as peer relationships may drive alcohol drinking 
(Leung et al, 2014), yet for others chronic alcohol drinking may lead to more automatic, habitual 
patterns of alcohol drinking behavior devoid of enjoyment (Barker and Taylor, 2014; O’Tousa 
and Grahame, 2014).  Although each of these factors deserves significant research attention in 
order to provide the most complete understanding of AUDs, the current dissertation will focus on 
two psychological processes:  positive-reinforcement and negative-reinforcement.  Positive-
reinforcement can be defined as the presentation of a rewarding experience or stimulus that 
increases the probability the individual will engage in a behavior- in this case alcohol drinking.  
On the other hand, negative reinforcement is the relief or avoidance of a negative experience or 
stimulus, which increases the probability of alcohol drinking behavior. 
 The euphoric, rewarding aspects of alcohol are believed to be largely mediated by the 
recruitment of the mesolimbic dopamine (DA) system- although it should be noted that other 
neurotransmitter systems contribute to alcohol use and abuse and have been comprehensively 
reviewed elsewhere (Sommer and Spanagel, 2013). Indeed, ethanol has long been shown to 
increase extracellular levels of DA in the nucleus accumbens (NAc; Di Chiara and Imperato, 
1988; Weiss et al, 1993).  Consistent with this observation, blocking DA signaling has been 
shown to reduce ethanol seeking behavior (Czachowski et al, 2001; Hodge et al, 1997; Rassnick 
et al, 1992).  Moreover, the positive-reinforcing properties of ethanol have been confirmed using 
a variety of behavioral paradigms.  For example, ethanol has been shown to reduce intracranial 
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self-stimulation thresholds (Lewis and June, 1990) and induces conditioned place preference 
(CPP) in rodents (Bozarth, 1990).  What is more, human imaging studies have revealed that 
alcohol and alcohol-related cues activate a number of regions within the reward system (Ingvar 
et al, 1998; Wrase et al, 2002) that leads to the release of DA within the ventral striatum 
(Boileau et al, 2003; Yoder et al, 2007).   Together, these data indicate that ethanol possesses 
positive-reinforcing properties through its activation of the mesolimbic dopaminergic reward 
system. 
 It is generally believed that the initial stages of ethanol use are driven by the positive-
reinforcing properties of the drug whereas negative-reinforcement becomes the more prominent 
motivator of ethanol abuse as neurobiological systems adapt to repeated ethanol challenges 
(Koob, 2003, 2013).  However, negative reinforcement may also contribute to the early stages of 
ethanol use as well.  In fact, numerous reports have described relatively high comorbidity rates 
of AUDs with stress/anxiety or major depression disorders (Arolt and Driessen, 1996; Kushner et 
al, 1990; Weissman et al, 1980).  Although these high rates of comorbidity cannot indicate 
causation, studies involving nonhuman primates have demonstrated that stressful experiences 
lead to increased ethanol drinking (Barr et al, 2004; Higley et al, 1991).  What is more, ethanol 
may help mitigate these psychologically unpleasant states.  In addition to producing a euphoric 
effect (see above), which may help relieve symptoms of depression, ethanol has also been shown 
to have anxiolytic effects.  Indeed, acute ethanol leads to a reduction in anxiety-like behavior in a 
number of different paradigms including open-field locomotor activity (Durcan and Lister, 1988) 
and the elevated plus maze (Pandey et al, 2008; Prunell et al, 1994).  Further investigation 
suggests that the anxiolytic properties of ethanol are believed to be due, in part, to its actions in 
the CeA (Pandey et al, 2008).  Together with the findings from the previous section regarding 
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the rewarding effects of ethanol, these data indicate that individuals may attempt to self-medicate 
with ethanol to achieve some semblance of relief from a negative affective state.  Consistent with 
this hypothesis, individuals who drink for similar reasons (i.e. negative-reinforcement) have been 
found to be at a greater risk of developing AUDs (Ray et al, 2009). 
Modeling Excessive Ethanol Consumption in the Laboratory 
As outlined above, excessive alcohol consumption is a complex human disorder that 
affects a large proportion of the population.  However, much of the research conducted in the 
laboratory uses animal models to investigate alcohol use, which is problematic as any one 
preclinical model is insufficient to address a multifaceted neuropsychological disorder such as 
AUDs.  For example, two-bottle choice tests are well-suited to examine ethanol preference 
(Spanagel, 2000), which can then be used to identify genetic markers that may increase the risk 
of alcohol use (Belknap et al, 1997; Phillips et al, 1994).  However, this procedure rarely yields 
physiologically relevant BECs, even in high-preferring strains of mice (Dole and Gentry, 1984), 
making it an unfit model to examine excessive ethanol consumption.  Alternatively, procedures 
that induce reinstatement of ethanol seeking behavior are an ideal model for investigating the 
neurobiology of ethanol relapse (Spanagel and Hölter, 2000), but cannot fully address the 
defining characteristics of binge alcohol drinking (i.e. achieving a BEC of at least 80 mg/dl in a 
short period of time).  Moreover,  other techniques that model excessive ethanol consumption 
rely on experimenter delivered ethanol via injection, gavage, or vapor inhalation (Gilpin et al, 
2008; Majchrowicz, 1975; Roberts et al, 2000) or may even require fluid deprivation (Cozzoli et 
al, 2009), the incorporation of ethanol in the animal’s diet (Roy and Pandey, 2002), or weaning 
the animal on sweetened ethanol (Koob and Weiss, 1990).  These methods introduce 
unnecessary confounds (e.g. stress, nutritional deficiencies, etc.) that could jeopardize 
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experimental interpretation.  Importantly, the neuroadaptive consequences of drugs of abuse can 
vary depending how the drug was delivered (Jacobs et al, 2003).  For these reasons, it is 
necessary that multiple models of AUDs be used to better capture the complexity of the human 
condition (Crabbe et al, 2011; Hines et al, 2005). 
Drinking in the Dark 
The “drinking in the dark” (DID) paradigm is a commonly used procedure to investigate 
binge-like ethanol intake in a preclinical model.  This paradigm takes advantage of the nocturnal 
nature of rodents to promote high levels of consumption during the dark cycle that generates 
physiologically relevant blood ethanol concentrations (BECs) of 80 mg/dl or greater  (Rhodes et 
al, 2005, 2007).  Though other mouse lines can be used in this model, C57BL/6J, which are 
genetically predisposed to drink ethanol (Belknap et al, 1993; Rodgers, 1967; Rodgers and 
McClearn, 1962), have been found to be the optimal mouse line that exhibits the highest levels of 
ethanol consumption in this model (Rhodes et al, 2007).  Importantly, further examination of this 
paradigm has indicated that DID-induced ethanol consumption does not stem from basic thirst 
(Rhodes et al, 2007) or caloric need (Lyons et al, 2008), which suggests that animals in this 
model are motivated to consume ethanol due to its post-ingestive effects rather than to maintain 
physiological homeostasis.  Moreover animals readily drink ethanol in the DID procedure- 
making other techniques such as sucrose fading, food/water deprivation, or other time consuming 
and/or stress-inducing paradigms unnecessary.  That said, it should be noted that mice that have 
experienced repeated binge cycles (up to 10 weeks) exhibited enhanced subsequent voluntary 
ethanol drinking, but did not show changes in anxiety-like behavior (Cox et al, 2013), which 
suggests that this procedure may not completely induce a transition to a dependence-like state in 
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the animals.  Nonetheless, the DID procedure is a powerful tool that can be used to model 
aspects of human binge drinking. 
The DID model also has the advantage of being a relatively simple procedure.  On days 
1-3 of the standard DID model, home-cage water bottles are removed three hours into the dark 
cycle and the animals are given access to test bottles containing ethanol (20% v/v) solution for 
two hours.  Binge-like consumption is assessed on the fourth day, the test day, in which the 
procedures are similar to the previous days except that access to ethanol is often extended to four 
hours.  After removing the ethanol bottles at the end of the four hour period on the test day, tail 
blood samples are collected from each animal in order to assess BECs. 
The Orexin System 
In 1998, two independent research groups simultaneously discovered the existence of a 
novel peptide. One group noted that this new peptide possessed structural similarities to the gut-
peptide, secretin, but displayed an expression pattern limited to the hypothalamus (de Lecea et 
al, 1998); thus, these researchers deemed this new peptide hypocretin (hypothalamus + secretin = 
hypocretin).  Alternatively, Sakurai and colleagues (1998) observed that the peptide was located 
in the hypothalamus, a brain region long-known for its critical involvement in feeding behavior 
(Brooks et al, 1946; Hetherington and Ranson, 1940).  After demonstrating that this peptide 
produced a robust feeding response these researchers named this peptide orexin (OX), which is 
derived from the Greek orexis meaning appetite.   
Cloning studies have revealed that the OX system is comprised of two peptides, orexin-A 
and orexin-B, which are derived from the precursor, prepro-orexin, and act on two G-protein 
coupled receptors, orexin-1 and orexin-2 receptors (OX1R and OX2R, respectively; de Lecea et 
al, 1998; Sakurai et al, 1998).  These peptides interact with equal affinity at the OX2R, but 
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orexin-A has been found to have a greater affinity for OX1R with orexin-B exerting minimal 
actions on OX1R (Sakurai et al, 1998).  Although neurons that synthesize OX peptide are 
restricted to the dorsal regions of the hypothalamus, orexinergic fibers project extensively 
throughout the brain and participate in a myriad of neurobiological functions.  In fact, the origin 
and target location of these orexinergic connections can provide insight into the function of the 
OX system.  For example, Sakurai and colleagues (1998) were able to shrewdly deduce its role 
in feeding behavior based solely on its limited expression within the hypothalamus.  In addition 
to feeding behavior, the hypothalamus is also involved in maintaining arousal (Vanni-Mercier et 
al, 1984).  It was suggested that the OX system also plays a role in sleep and arousal when it was 
observed that regions critically involved in this behavior- such as the tuberomammillary nucleus, 
raphe nuclei, and locus coeruleus- were densely innervated by OX neurons (Peyron et al, 1998).  
Shortly thereafter, it was demonstrated that proper OX functioning was necessary to maintain 
healthy waking states (Chemelli et al, 1999; Lin et al, 1999).  Additionally, Peyron and 
colleagues (1998) also observed that OX neurons project the ventral tegmental area (VTA), the 
nucleus accumbens (NAc), amygdala, and bed nucleus of the stria terminals, which are regions 
known to be involved in reward and/or stress processing.  Consistent with these projection 
patterns, it was later demonstrated that OX also modulates the positive reinforcing effects of 
rewards (Harris et al, 2005) as well as stress responding (Kuru et al, 2000). 
What is more, it has been proposed that hypothalamic OX can be dichotomized based on 
distinct functional attributes. Specifically, lateral hypothalamic (LH) OX neurons have been 
postulated to be more involved in feeding and reward-related behaviors (Harris et al, 2005) while 
OX neurons from the perifornical area of the hypothalamus (PFA) and dorsomedial 
hypothalamus (DMH) are believed to be more associated with stress and arousal (Harris and 
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Aston-Jones, 2006). Moreover, this dichotomy generalizes to the receptors as well; OX1R is 
more associated with reward processing (Smith et al, 2009) and OX2R with wakefulness and 
arousal (Akanmu and Honda, 2005; Willie et al, 2003).  However, more recent findings indicate 
that such a clear segregation of OX function based simply on hypothalamic origin may not be as 
apparent as originally believed (González et al, 2012). 
Orexin and Reward 
The hypothalamus has been known for well over fifty years to be integrally involved in 
reward-related behaviors (Olds, 1958; Olds and Milner, 1954).  Consistent with these findings, 
hypothalamic OX projections facilitate the activity of several brain regions in the reward circuit, 
such as the VTA (Korotkova et al, 2003; Moorman and Aston-Jones, 2010; Vittoz et al, 2008) 
and shell of the NAc (NAcSh; Mori et al, 2010; Mukai et al, 2009).  It is believed that OX 
mediates the positive-reinforcing effects of rewarding stimuli by modulating activity of VTA DA 
neurons.  In fact, both orexin-A (Borgland et al, 2006) and orexin-B (Borgland et al, 2008) have 
been found to strengthen glutamatergic transmission onto VTA DA neurons that serve to 
enhance neuronal excitability within the VTA.  Furthermore, treatment with OX peptide into the 
VTA (Korotkova et al, 2003; Narita, 2006) and NAcSh (Patyal et al, 2012) leads to elevated 
mesolimbic DA release.  Moreover, central infusions of OX have been found to be reinforcing in 
a DA-dependent manner as local infusions of orexin-A into the VTA produced conditioned place 
preference (CPP), which was blocked by concomitant infusion of a DA receptor antagonist 
directly into the NAc (Taslimi et al, 2012).  These findings and others provide a theoretical 
framework to aid in the understanding of how OX may modulate the neurobiological responses 
to various drugs of abuse (see Mahler et al. 2012 for review).  
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Orexin and Stress 
 Early researchers investigating the neurobiological mechanisms of the stress-response 
system recognized the relationship between adrenocorticotrophic hormone (ACTH) release from 
the pituitary gland and the subsequent release of corticosterone in response to a stressor (Sayers 
and Sayers, 1949); however, the role of the hypothalamus in this stress-response system was 
relatively poorly understood for several years to follow (Katsuki et al, 1955).  Since that time, 
the hypothalamus has been firmly established as a critical modulator of stress and anxiety- a fact 
perhaps best illustrated by its inclusion in the name of the predominate stress system, the 
hypothalamic-pituitary-adrenal (HPA) axis.  In accordance with its restricted expression within 
the hypothalamus, the OX system has been found to regulate stress responding.  
Intracerebroventricular (i.c.v.) infusion of orexin-A has been shown to activate the 
paraventricular nucleus of the hypothalamus (PVN; Kuru et al, 2000)- the subregion of the 
hypothalamus that expresses corticotropin releasing factor (CRF) that initiates a stress response 
from the HPA axis.  Not surprisingly, this group went on to demonstrate that similar i.c.v. 
infusion of OX leads to an increase in circulating ACTH and corticosterone levels.  Moreover, 
hypothalamic OX neurons are activated in response to an environmental stressor (Sakamoto et 
al, 2004; Winsky-Sommerer et al, 2004).  Indeed, OX neurons have been shown to possess 
reciprocal connections with CRF neurons (Winsky-Sommerer et al, 2004) and OX is capable of 
activating CRF neurons of the HPA axis as well as extra-HPA axis CRF neurons within the 
central nucleus of the amygdala (CeA; Sakamoto et al, 2004).  In humans, OX levels have been 
found to be directly correlated with increased symptoms of anxiety (Johnson et al, 2010).  
Together, these data indicate that OX participates in stress and anxiety, in part, through its 
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connections with the CRF system- although the OX system also does so through other 
neurobiological means beyond just the CRF system (see Johnson et al, 2012 for review). 
Ethanol Engages the Orexin System 
Multiple studies have reported that experience with ethanol recruits the OX system.  This 
relationship was first observed by Lawrence and colleagues (2006) when they reported that 
chronic ethanol drinking increased OX mRNA in the LH relative to ethanol naïve rats.  
Interestingly, Morganstern and colleagues (2010) reported that chronic ethanol consumption 
caused a significant reduction in hypothalamic OX mRNA while acute ethanol exposure 
significantly enhanced OX mRNA and orexin-A levels.  What is more, Barson and colleagues 
(2014) recently assessed changes in OX mRNA following ethanol drinking in an intermittent-
access paradigm and found increased OX expression in the hypothalamus.  A similar pattern of 
effects has also been observed in ethanol seeking behavior.  Indeed, context-induced renewal of 
ethanol seeking behavior was found to activate OX neurons in the DMH and LH, but not PFA 
while ethanol preference and seeking in the homecage was positively correlated with OX activity 
in the LH and PFA, but not DMH (Moorman et al, 2016).  The literature investigating changes in 
OXRs in response to ethanol drinking is relatively sparse; however, increases in OX2R levels in 
the anterior paraventricular nucleus of the thalamus were observed following ethanol drinking 
(Barson et al, 2014).  Similarly, a strong, positive correlation has been observed between ethanol 
consumption and hypothalamic OX1R expression- though this effect did not reach significance 
(Pickering et al, 2007). As a whole, a pattern emerges from this collection of findings that 
suggests that ethanol exposure results in an upregulated OX system.  Whether or not binge-like 
ethanol consumption similarly perturbs the OX system, however, has yet to be determined.  
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Given the need to approach AUDs from multiple different perspectives (i.e. models), further 
examination of how this peptide system responds to binge-like ethanol drinking is necessary.  
The Orexin System Modulates the Neurobiological Responses to Ethanol 
Findings outlined in the previous section suggest that ethanol drinking is associated with 
elevated activity in the OX system; thus, it stands to reason that pharmacological manipulations of 
OX signaling would impact ethanol intake.  Indeed, Lawrence and colleagues (2006) confirmed 
such an effect when they demonstrated that a systemic injection of the selective orexin-1 receptor 
antagonist, SB-334867 (SB), reduced operant self-administration of ethanol.  Similarly, SB was 
found to reduce ethanol consumption and preference in high ethanol preferring rats (Moorman and 
Aston-Jones, 2009).  Further investigations suggest that modulation of OX signaling via SB may 
be specific to ethanol as Jupp and colleagues (2011) found that SB significantly attenuated the 
motivational effects of ethanol but not sucrose.  Although these data suggest an essential role for 
OX1R signaling in ethanol drinking, recent evidence suggests the OX2R is also capable of 
modulating responses to ethanol (Anderson et al, 2014; Barson et al, 2014; Shoblock et al, 2011).  
Moreover, more comprehensive investigations of the role of OX in ethanol drinking have revealed 
that signaling within reward-related structures is responsible for modulating this behavior.  Indeed, 
direct infusions of orexin-A in the LH or PVN increased ethanol drinking (Schneider et al, 2007) 
while a non-selective OXR antagonist into the VTA significantly decreased ethanol self-
administration (Srinivasan et al, 2012).  As a whole, these findings indicate ethanol drinking 
directly parallels OX signaling in the reward pathway.   
Recent evidence suggests that OX may mediate ethanol responding by both modulating 
its reinforcing properties as well as recruiting stress-related circuitry.  Indeed, systemic 
antagonism of the OX2R blocks ethanol-induced CPP (Shoblock et al, 2011) and suppression of 
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systemic OXR signaling reduces breakpoints for ethanol responding in a progressive ratio 
schedule of reinforcement (Anderson et al, 2014; Jupp et al, 2011a).  Additionally, SB blocks 
yohimbine-induced renewal of ethanol seeking behavior (Richards et al, 2008)- a procedure that 
engages stress-related systems (Funk et al, 2006; Vythilingam et al, 2000) and is thought to 
model stress-induced relapse of drug seeking behavior (Feltenstein and See, 2006; Lee et al, 
2004).  Beyond preclinical studies, OX levels have been found to be directly correlated with 
severity of alcohol withdrawal symptoms in humans (Bayerlein et al, 2011; von der Goltz et al, 
2011).  Together, these data support the notion that OX may regulate ethanol responding through 
both positive- and negative-reinforcement. 
Despite these findings, the role of the OX system in binge-like drinking remains relatively 
unexplored. Considering recent evidence from our lab indicates binge-like ethanol drinking recruits 
different neurocircuitry relative to moderate-level ethanol consumption (Lowery et al, 2010; 
Lowery-Gionta et al, 2012; Sparta et al, 2008), examination of the participation of this peptide 
system in binge-like ethanol drinking is necessary.  To date, we and others have demonstrated that 
systemic inhibition of signaling onto OX1Rs (Olney et al, 2015) and/or OX2Rs (Anderson et al, 
2014) disrupts binge-like ethanol drinking without impacting general locomotor behavior.  
However, this effect was not specific to ethanol as these studies also showed that OXR antagonists 
similarly reduced binge-like sucrose and saccharin consumption, which suggests that OX may 
modulate binge-like consumption of general, salient reinforcer regardless of nutritional content.  
Taken together, these data clearly demonstrate that OX is involved in binge-like ethanol drinking 
behavior; however, further investigation is required in order to identify the brain regions that 
specifically modulate this effect. 
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Goals of the Current Dissertation 
Broadly, the primary goal of the current dissertation is to provide a detailed 
characterization of the OX system in binge-like ethanol drinking behavior.  This will be achieved 
using two main strategies:  describing the effect of binge-like ethanol drinking on the OX system 
and characterizing the specific OX neurocircuitry involved in this behavior.  The second chapter 
will describe how repeated episodes of binge-like ethanol drinking impacts different facets of the 
OX system.  Here, we will examine changes in orexin-A and -B in hypothalamic subregions via 
immunohistochemistry.  Additionally, we will use polymerase chain reaction to examine 
alterations in the expression of prepro-orexin mRNA within the hypothalamus and attempt to 
identify changes in OX1R and OX2R mRNA expression in the hypothalamus as well as OX 
projection regions relevant to ethanol drinking:  the VTA and amygdala.  The next two chapters 
will investigate the contribution of each OXR subtype within brain regions involved in reward- 
and stress-related processing.  The third chapter will characterize the OX neurocircuitry within 
the VTA while the fourth will focus on that of the CeA.  Additionally, these chapters will 
elucidate the overarching psychological process that modulates this behavior by also 
investigating whether OXR signaling in the VTA and CeA influences anxiety-like behavior.  
Findings obtained from this series of experiments will provide valuable insight into the 
neurobiological mechanisms that underlie binge-like ethanol drinking behavior and will greatly 
expand our current understanding of the contribution of the OX system in binge-like ethanol 
drinking behavior.  Importantly, these findings may greatly inform the development of 
pharmacological interventions to be used to treat AUDs and may reveal the OX system as a 
potential target for such treatment options. 
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CHAPTER 2 
THE EFFECTS OF BINGE-LIKE ETHANOL CONSUMPTION  
ON THE OREXIN SYSTEM 
Introduction 
The two peptides of the orexin (OX) system, orexin-A and orexin-B, are 33- and 28-
amino acid sequences, respectively, that are cleaved from the precursor, prepro-orexin (de Lecea 
et al, 1998; Sakurai et al, 1998).  Neurons that produce these peptides are restricted to the 
hypothalamus; however, these neurons send widespread projections to a number of regions 
throughout the brain.  OX peptides from these fibers act on two receptors, the orexin-1 (OX1R) 
and orexin-2 receptor (OX2R), to influence a wide array of neurobiological functions including 
feeding (Sakurai et al, 1998), sleep (Chemelli et al, 1999), stress (Kuru et al, 2000), and reward 
(Harris et al, 2005).  Interestingly, although there is a high degree of overlap in expression 
between the OXRs, the two subtypes display differential expression in some brain areas.  For 
example, it has been reported that both receptors are moderately expressed in the ventral 
tegmental area (VTA) yet the OX1R is more densely expressed in the extended amygdala as well 
as the prelimbic and infralimbic cortices while the OX2R is more robustly expressed throughout 
much of the hypothalamus and the lateral habenula in the rat brain (Marcus et al, 2001).   
These findings suggest a degree of separation in how each subtype participates in 
different functions.  Indeed, the OX system has been shown to modulate the sensitivity of other 
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homeostatic regulators with the OX1R controlling insulin sensitivity (Shiuchi et al, 2009) while 
the OX2R controls leptin sensitivity (Funato et al, 2009).  Perhaps the most notable distinction is 
regarding the involvement in reward and arousal, which are modulated by the OX1R and OX2R, 
respectively (Dugovic et al, 2009; Gozzi et al, 2011; Harris et al, 2005; Lin et al, 1999; 
Malherbe et al, 2009; Smith et al, 2009).  Considering that neurons originating from the lateral 
hypothalamus (LH) have been reported to be more involved in reward while those of the 
dorsomedial and perifornical regions (DMH and PFA, respectively) predominately contribute to 
arousal and stress (Harris and Aston-Jones, 2006), these functional differences may arise from 
differences in anatomical sources of orexinergic fibers as well. 
Moreover, both OXRs have been implicated in ethanol drinking (Anderson et al, 2014; 
Srinivasan et al, 2012), although disparities still exist in how each subtype contributes to 
neurobiological responses to ethanol.  For example, Barson and colleagues (2014) demonstrated 
that the OX2R, but not OX1R, within the anterior paraventricular nucleus of the thalamus 
(aPVT) modulates ethanol consumption.  Similarly, Shoblock and colleagues (2011) showed that 
treatment with an OX2R antagonist blocked ethanol-induced conditioned place preference- an 
effect that was not observed following OX1R inhibition.  Together, these data and others indicate 
that the two OXR subtypes may be differentially involved in the neurobiological responses to 
ethanol.   
What is more, multiple sources have reported observing ethanol-induced changes in the 
OX system.  Specifically, a rather consistent pattern of effects has emerged that suggests that 
exposure to ethanol causes subsequent increases in OX levels (Lawrence et al, 2006; 
Morganstern et al, 2010).  Relatively few studies have investigated relative differences in OX 
expression between the two peptides and/or receptors.  However, what little evidence exists 
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suggests different aspects of the OX system undergo changes following experience with ethanol.  
Indeed, the aPVT shows elevated OX2R, but not OX1R, mRNA expression after ethanol 
exposure (Barson et al, 2015).  Furthermore, this same study also reported no such changes in 
the posterior PVT, which suggests that changes in the OX system are not only specific to certain 
aspects of the OX system (e.g. receptor subtype) but also to particular regions of the brain. 
As it stands, the current literature suggests that ethanol exposure leads to plastic changes 
in the OX system.  However, the perturbations of the OX system following binge-like ethanol 
drinking behavior remain relatively unknown.  Therefore, the purpose of the present study was to 
characterize the changes in the OX system following binge-like ethanol drinking using the 
“drinking in the dark” (DID) paradigm.  These changes were assessed using real-time 
polymerase chain reaction (RT-PCR) to measure mRNA expression of prepro-orexin and each 
OXR subtype in the hypothalamus as well as the ventral tegmental area (VTA) and amygdala- 
two regions that receive dense orexinergic projections and are involved in ethanol drinking 
(Engel and Jerlhag, 2014; Gilpin et al, 2015; Peyron et al, 1998).  To further characterize the 
effect of binge-like ethanol drinking on the OX system, levels of orexin-A and orexin-B were 
directly assessed using immunohistochemistry (IHC) within the LH, PFA, and DMH. 
Methods 
Animals 
Male C57BL/6J mice (C57; Jackson Laboratories, Bar Harbor, ME), aged 6-7 weeks and 
weighing 20-25 g upon arrival, were used in each of the following studies.  Mice were 
individually housed in plastic cages located in a vivarium with an ambient temperature of 
approximately 22ºC and a reverse light/dark cycle with lights off at 8:30 am.  All animals had ad 
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libitum access to food and water except when specified below.   All procedures used were in 
accordance with the National Institute of Health guidelines and were approved by the University 
of North Carolina Institutional Animal Care and Use Committee. 
Drinking in the Dark 
Three groups of fifty C57 mice experienced one or three cycles of “drinking-in-the-dark” 
(DID) in order to assess changes in the OX system following binge-like drinking behavior using 
immunohistochemistry (IHC) and RT-PCR.  One cohort each was used for the orexin-A IHC, 
orexin-B IHC, and RT-PCR experiments.  The DID procedure is a commonly used animal model 
of binge-like ethanol drinking that promotes high levels of consumption and generates 
physiologically relevant blood ethanol concentrations (BECs) of 80 mg/dl or greater (Rhodes et 
al, 2005, 2007). On days 1-3, standard water bottles were removed three hours into the dark 
cycle and the animals were given access to test bottles containing water, ethanol (20% v/v), or 
sucrose (3% w/v) solutions for two hours.  Binge-like consumption was assessed on the fourth 
day when access to the test bottles was extended to four hours.  Each four day testing period 
constituted a binge cycle, and there were 3 days with no ethanol access between binge cycles.  
The start dates of the binging cycles were staggered such that all groups finished testing on the 
same day and at the approximate same age.   Moreover, all animals were sacrificed and perfused 
immediately following the final binge session in order to assess changes in the OX system while 
ethanol was still present in the brain. 
Immunohistochemical Analysis 
On the final day of testing, tail-bloods were collected and analyzed using the Analox 
blood ethanol analyzer (Analox Instruments, Luneburg, MA) to measure BEC.  To ensure 
consistency across all groups, tail-bloods were collected from all animals; however, only those 
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blood samples from animals in the one and three cycle ethanol groups were analyzed.  Animals 
were then sacrificed and transcardially perfused with 0.1 mM phosphate-buffered saline (PBS; 
pH7.4) followed by 4% paraformaldehyde in phosphate buffer.  Brains were then collected and 
post-fixed in paraformaldehyde for 48 hr at 4°C, at which point they were transferred to PBS.  
The brains were cut using a vibratome (Leica Microsystems, Buffalo Grove, IL) into 40 μm 
sections that were stored in cryopreserve until the IHC assay.  Sections were then transferred to 
PBS for 24 hr before processing with orexin-A or orexin-B antibodies.  After rinsing in fresh 
PBS 4 times (10 minutes each), tissue sections were blocked in 10% goat serum and 0.1% triton-
X-100 in PBS for 1 hour.  Sections were then transferred to fresh PBS containing primary 
antibody for 72 hr at 5°C.  Protein expression was detected using primary antibody against 
orexin-A (1:5000, Santa Cruz Biotechnology, Dallas, TX) or orexin-B (1:5000, Santa Cruz 
Biotechnology, Dallas, TX).  After the 72 hr of incubation with antibody, the sections were 
rinsed four times and then processed with Vectastain Elite kits (Vector Labs, Burlingame, CA).  
The sections processed for orexin-A and -B were visualized by reacting the sections with a 3,3′-
diamino-benzidine tetrahydrochloride (DAB; Polysciences, Inc., Warrington, PA) reaction 
solution containing 0.05% DAB, 0.005% cobalt, 0.007% nickel ammonium sulfate, and 0.006% 
hydrogen peroxide.  
Digital images of peptide immunoreactivity (IR) were then obtained on a Nikon E400 
microscope equipped with a Nikon Digital Sight DS-U1 digital camera run with Nikon-provided 
software. Immunoreactive neurons were counted using Image-Pro Plus software 
(MediaCybernetics, Rockville, MD).  Anatomically matched pictures of the left and right sides 
of the brain were used to produce an average cell count for each hypothalamic subregion (LH, 
PFA, and DMH) of each animal.  Only one section per side was analyzed in the current study.  
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The section for each animal was selected as the section with the most robust OX expression 
observed in the hypothalamus, which was approximately 1.06 to 1.34 mm posterior to bregma.  
The entire 40 µm section was examined.  We adopted the boundaries set forth by Mahler and 
Aston-Jones (2012) for the current experiment (Fig. 2.1).  Specifically, cells were qualified as 
LH OX cells if they were in the lateral portions of the hypothalamus between the internal capsule 
and the lateral edge of the fornix.  Neurons found within the lateral edge of the fornix to the 
lateral edge of the mammillothalamic tract were considered cells of the PFA.  Finally, neurons in 
the most medial portions of the hypothalamus between the lateral edge of the mammillothalamic 
tract and the third ventricle were recorded as DMH cells.  However, upon initial quantification of 
the levels of orexin-A positive cells in our animals, it became clear that the DMH exhibited 
minimal orexin-A IR in our samples (grand mean: 3.327, SEM: 0.352); therefore, this subregion 
was removed from further analysis of both orexin-A and orexin-B peptides. 
Real Time Polymerase Chain Rection 
 On the final day of DID testing, brains were immediately extracted via rapid decapitation 
and flash frozen using isopentane and stored at -80°C.  Blood samples were collected 
immediately following rapid decapitation for the one and three cycle ethanol groups in order to 
assess BECs as described above.  Bilateral cylindrical punches (1 mm x 1mm) containing target 
brain structures were collected from each brain and immediately submerged in RNALater 
(Ambio; Carlsbad, CA) per the manufacturer’s instructions.  Punches containing the 
hypothalamus and amygdala were taken starting at 1.70mm posterior to bregma while punches 
containing the VTA were taken 3.08mm posterior to bregma.  RT-PCR analysis of mRNA 
expression was performed by the UNC Animal Clinical Chemistry and Gene Expression 
Laboratories and has been described previously (Kim et al, 2002).  The nucleotide sequences for 
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the PCR primers and fluorogenic probes used in the analysis were as follows:  prepro-orexin 
forward:  5'-AGG CCT CCA GGG ACG GCT-3', reverse:  5'-CAT GGT CAG GAT GCC AGC 
T-3', probe:  5'-FAG CGC CTC CTT CAG GCC AAC GGT A Q-3'; OX1R forward:  5'-CTT 
CTC CCA CTG GCT AGT GT-3', reverse:  5'-TGC TCC CGG AAT TTG CCA CT-3', probe:  
5'-FTG CCG CCA ACC CTA TCA TCT ACA AC Q-3'; OX2R forward:  5'-CTC ACC AGC 
ATA AGC ACA CT-3', reverse:  5'-TGG TAC TCC CTG CTG TAG AT-3', probe:  5'-FTG 
AAG CGG TCC TGC CCC GTT GGC Q-3'; β-actin forward:  5'-CTG CCT GAC GGC CAG 
GTC-3', reverse:  5'-CAA GAA GGA AGG CTG GAA AAG A-3', probe:  5'-FCA CTA TTG 
GCA ACG AGC GGT TCC GQ-3'.  Measurements were normalized to the water control group 
and presented as percent change from controls. 
Data Analysis 
Separate univariate ANOVAs were used to measure either orexin-A or orexin-B positive 
cells in either the LH or PFA using group (water, one-cycle ethanol, one-cycle sucrose, three-
cycle ethanol, or three-cycle sucrose) as the independent variable.  Similarly, separate univariate 
ANOVAs were also used to measure prepro-orexin, OX1R, or OX2R expression in the 
hypothalamus, amygdala, or VTA using group (water, one-cycle ethanol, one-cycle sucrose, 
three-cycle ethanol, or three-cycle sucrose) as the independent variable.  The brain tissue from an 
animal in the three-cycle ethanol group was damaged during the orexin-A staining process 
making it unable to be quantified and was removed from the analysis.  To ensure that 
hypothalamic OX expression was not affected by differential drinking levels, separate t-tests 
were used to assess consumption of each test solution (i.e. ethanol or sucrose) on the final day of 
testing between animals in the one or three DID cycle groups.  Similarly, a t-test was also 
performed on the BEC data to measure differences in ethanol metabolism as a function of DID 
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cycles (one or three).  Finally, separate univariate ANOVAs were used to analyze changes in 
body mass (g) as a function of group.  Tukey’s LSD post-hoc tests and Bonferroni corrections 
were used when applicable.   
Results 
Animals’ responses to the test solutions were comparable regardless of DID history as 
ethanol and sucrose drinking on the final day of testing did not differ between animals that 
experienced one- or three-cycles of DID (Figure 2.2A,C; t(18) = 0.1316, p = 0.897; t(18) = 0.4746, 
p = 0.641; respectively).  Additionally, both groups of ethanol drinkers achieved similar BECs 
regardless of DID history (Figure 2.2B; t(18) = 0.603, p = 0.5540).  Moreover, no differences 
across any of the groups were observed in body mass as measured at the end of testing (Figure 
2.2D; F(4, 45) = 0.541, p = 0.706). 
Our analysis revealed that binge-like consumption of ethanol or sucrose solutions 
significantly altered the number of orexin-A positive neurons within the LH (Figure 2.3A-F; 
F(4,48) = 5.863, p = 0.001).  Further probing of this effect revealed that relative to the water group 
(Figure 2.3B) all test groups (i.e. one-cycle ethanol (Figure 2.3C), three-cycle ethanol (Figure 
2.3D), one-cycle sucrose (Figure 2.3E), and three-cycle sucrose (Figure 2.3F)) displayed 
significantly reduced OX levels (Fig. 1A; p’s < 0.010).  Similarly, binge-like consumption of 
ethanol or sucrose also significantly altered OX levels within the PFA (F(4,48) = 3.702, p = 
0.011).  Unlike the LH, however, Tukey’s LSD tests indicated that only the three-cycle ethanol 
group showed significant reductions in OX expression in the PFA relative to the water group (p 
= 0.006). 
Our second cohort of animals used to investigate orexin-B IR also displayed comparable 
levels of binge-like ethanol (Figure 2.4A; t(15) = 0.697, p = 0.497) and sucrose (Figure 2.4C; t(17) 
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= 0.622, p = 0.542) consumption as well as BECs (Figure 2.4B;t(15) = 0.480, p = 0.638) 
regardless of the number of DID cycles.  Consistent with the previous cohort, no differences 
were observed in body mass as a function of group (Figure 2.4D; F(4, 47) = 0.338, p = 0.851). 
As with the last analysis, we observed that binge-like consumption significantly impacted 
levels of orexin-B in the LH and PFA (Figure 2.5A-F; F(4,39) = 4.410, p = 0.005; F(4,39) = 4.891,  
p = 0.003; respectively).  Further probing of the effect within the LH revealed that the one-cycle 
ethanol group (Figure 2.4C) displayed significantly reduced orexin-B levels relative to water 
drinking controls (Figure 2.4B; p = 0.005) as well as relative to the three-cycle ethanol group 
(Figure 2.4D; p = 0.005).  Within the PFA, post-hoc analyses revealed that both the one-cycle 
ethanol and one-cycle sucrose groups exhibited orexin-B levels that were significantly lower 
than the water drinking controls (p = 0.002 and p = 0.001, respectively). 
The group of animals used in the PCR study displayed statistically similar levels of 
binge-like ethanol (Figure 2.6A; t(18) = -0.935, p = 0.362) and sucrose (Figure 2.6C; t(18) = -0.795, 
p = 0.437) consumption as well as BECs (Figure 2.6B; t(18) = 1.468, p = 0.159) regardless of the 
number of DID cycles.  The body mass of the animals did not vary as a function of group (Figure 
2.6D; F(4, 45) = 0.828, p = 0.515). 
We detected a significant difference in prepro-orexin expression within the hypothalamus 
as a function of group (Figure 2.7A; F(4, 45) = 5.558, p = 0.001).  Here, the three-cycle sucrose 
group was found to have significantly great precursor mRNA relative to all of the other groups 
except the one-cycle ethanol group (p’s ≤ 0.002).  We did not observe any significant changes in 
OX1R mRNA expression as a function of group in the hypothalamus (Figure 2.7B; F(4, 45) = 
0.712, p = 0.588) or VTA (F(4, 45) = 0.339, p = 0.850).  However, we did observe significant 
alterations in OX1R expression within the amygdala (F(4, 45) = 5.688, p = 0.001), which was 
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driven by the fact that the three-cycle ethanol group displayed elevated OX1R mRNA relative to 
the water group (p < 0.001) and one-cycle sucrose group (p = 0.003).  Levels of OX2R mRNA 
were below detectable levels in the amygdala and VTA; thus, we were unable to analyze those 
results.  However, there was sufficient OX2R expression within the hypothalamus, but no 
differences were observed in this region (Figure 2.7C; F(4, 43) = 0.727, p = 0.578). 
Discussion 
 It has previously been reported that experience with ethanol engages the OX system and 
causes changes to peptide and/or receptor levels (Barson et al, 2015; Lawrence et al, 2006; 
Morganstern et al, 2010).  Findings from the current studies expand upon our current 
understanding by demonstrating that binge-like ethanol drinking similarly alters the OX system.  
Moreover, further examination indicates that these changes are not due to differences in ethanol 
consumption, BECs, or body mass but rather are due to exposure to ethanol.   
Our first experiment revealed that the levels of hypothalamic orexin-A are reduced 
following repeated cycles of binge-like ethanol drinking.  Moreover, this effect was not specific 
for ethanol as a similar pattern of results was observed among animals that experienced binge-
like sucrose consumption.  However, these effects were specific to the LH, a subregion 
hypothesized to be mainly involved in reward processing (Harris et al, 2005), as we observed 
minimal changes in the PFA, a subregion believed to be more involved in stress and arousal 
(Harris and Aston-Jones, 2006).  Although we observed an increase in orexin-A IR in the PFA 
among animals that experience three cycles of binge-like ethanol consumption, this effect may 
be due to ethanol’s influence on normal sleep patterns (Ebrahim et al, 2013).  Indeed, ethanol has 
been shown to promote sleep by inhibiting OX neurons in the PFA (Sharma et al, 2014).   
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Our orexin-A IR data appears to provide support for the dichotomy of OX function 
between the LH and PFA in processing reward and arousal/stress, respectively (Harris and 
Aston-Jones, 2006).  Our findings of the changes in orexin-B, on the other hand, do not support 
this theory.  Similar to orexin-A, we observed that levels of orexin-B decline following binge-
like ethanol and sucrose.  Unlike the other peptide, however, this reduction in orexin-B was 
observed in both the LH and PFA- indicating an absence of functional dichotomy.  In fact, there 
are several other examples in the literature that do not support the idea of a clear separation of 
OX function between the LH and PFA.  Most notably, González and colleagues (2012)  infused 
retrograde tracers directly into the locus coeruleus (LC) and VTA- two regions that receive dense 
orexinergic input that are critically involved in sleep and reward, respectively- and found that 
OX neurons within the LH and PFA each projected substantially to both the LC and VTA.  In 
fact, the authors even reported that OX neurons within the LH were more likely to project to the 
LC than the VTA.  As a whole, these data indicate that the functional roles of OX cannot be so 
clearly segregated based on hypothalamic origin.   
Contrary to our findings with orexin-A, we also observed that the decline of orexin-B 
positive neurons was transient.  Specifically, we observed a reduction in orexin-B IR following 
one-cycle of binge-like consumption of a salient reinforcer; however, levels returned back to 
baseline for the animals that experienced three-cycles of DID.  This suggests that orexin-B is 
initially engaged during the early stages of DID but is no longer recruited with repeated use.   In 
terms of alcohol-use disorders, this may suggest that orexin-B is involved in the initial stages of 
alcohol use but does not contribute the maintenance of binge-like ethanol drinking.  It should be 
noted that the animals used to assess orexin-B IR drank lesser amounts of ethanol and sucrose 
and had lower resulting BECs relative to those animals used to assess orexin-A IR and OX 
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mRNA (Figure 2.2, 2.4, & 2.6).  This difference in consumption likely stems from the different 
food diet that these animals were given during binge testing, which has been found to drastically 
affect ethanol consumption (Marshall et al, 2015).  Despite the lower levels of consumption in 
these animals, we nonetheless observed group differences in orexin-B IR. 
Although we observed a reduction in the number of OX peptide IR neurons following 
binge-like ethanol drinking, we did not observe a similar effect when we measured mRNA 
expression.  Specifically, expression of the precursor, prepro-orexin, did not change following 
one or three cycles of binge-like ethanol consumption.  However, mRNA expression 
significantly rose following three-, but not one-, cycles of sucrose DID.  Similarly, we found that 
three-, but not one-, cycles of sucrose DID led to elevated OX1R mRNA expression within the 
amygdala.  However, no significant change in OX1R mRNA was observed in the hypothalamus, 
VTA, or amygdala following binge-like ethanol drinking.  Moreover, no alterations in OX2R 
mRNA were detected in the hypothalamus of any group.  Together, these data indicate that 
production of OX peptides and receptors remain largely unaltered following binge-like ethanol 
consumption and suggest that binge-like ethanol drinking does not induce plastic adaptations in 
the OX system.   
 Previous studies have reported that ethanol consumption upregulates of the OX system by 
increasing prepro-orexin mRNA expression in the hypothalamus  (Barson et al, 2015; Lawrence 
et al, 2006).  Similarly, pharmacological studies indicate that ethanol consumption parallels OX 
signaling by showing that OX agonists increase ethanol consumption (Barson et al, 2015; 
Schneider et al, 2007) while antagonists reduce ethanol intake (Anderson et al, 2014; Jupp et al, 
2011a; Lawrence et al, 2006; Moorman and Aston-Jones, 2009; Olney et al, 2015; Srinivasan et 
al, 2012).  In light of these reports, we believe our observed reduction in OX peptide IR reflects 
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an increase in OX signaling.  In this case, OX would be released from its presynaptic stores in 
response to consumption of salient reinforcers.  As our IHC analysis measured the amount of 
peptide immediately following the last round of DID, a reduction in orexin-A and -B IR may be 
a sign of depleted stores of OX peptide due to an increase in signaling.  Findings from our PCR 
analysis appear to support this hypothesis.  Specifically, a reduction in prepro-orexin mRNA 
would have indicated a downregulation in the OX system following binge-like ethanol drinking.  
In this case, DID would have led to decreases in both OX peptide IR and precursor mRNA.  
However, we did not observe this to be the case.  Instead, we found that expression of prepro-
orexin mRNA remained unchanged following binge-like ethanol drinking.  Thus, rather than a 
downregulated OX system, the reduced OX peptide IR is most likely a consequence of 
diminished OX levels due to increased release. 
It should be noted that some details of the results from the PCR analysis were rather 
unexpected.  First, we did not observe significant changes in hypothalamic prepro-orexin mRNA 
following binge-like ethanol consumption.  This is inconsistent with the majority of the existing 
literature, which indicates that precursor mRNA is elevated following experience with ethanol.  
However, other reports exist that do not align with this pattern of results.  For example, chronic 
ethanol consumption tends to increase OX mRNA (Barson et al, 2015; Lawrence et al, 2006).  
However, Morganstern and colleagues (2010) reported that acute ethanol caused an increase in 
OX expression while chronic ethanol consumption actually resulted in a significant reduction in 
hypothalamic OX mRNA.  Given that different models of ethanol exposure can lead to differential 
effects on the OX system, it may be that binge-like ethanol drinking using the DID procedure 
simply does not lead to compensatory changes in the OX system.  Alternatively, the timing of the 
tissue collection may have impacted the results as well.  For example, we sacrificed our animals 
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immediately after the final binge session whereas others waited 30 min (Barson et al, 2015) or two 
hours (Morganstern et al, 2010) afterwards to assess OX mRNA.  In the case of prepro-orexin 
expression we may have collected tissue before the system responded to the depleted levels of OX 
peptide and mobilized prepro-orexin mRNA to replenish those levels.  Future studies may benefit 
from waiting longer after the final binge session to assess OX mRNA levels. 
Furthermore, we did not expect expression of OX2R mRNA to be so low as to be largely 
undetectable in our PCR analysis.   That being said, the pattern of regional OX2R expression- 
particularly the low expression of this receptor subtype- is consistent with the existing literature 
(Marcus et al, 2001).  Other investigators have opted to pool tissue samples in order to augment 
the signal (Morganstern et al, 2010) and it remains to be seen whether a similar strategy would 
have resolved this issue in our analysis.  In this case, combining tissue samples from mice with 
comparable drinking levels may have sufficiently improved the OX2R mRNA signal to allow for 
adequate statistical analysis and interpretation of subsequent results.  However, we chose not to 
pool the samples in the current study as we only had 10 animals per group.  Pooling the tissue 
may have improved the signal, but halving our sample size would have drastically reduced our 
statistical power- impeding our ability to detect statistical differences in OX expression. 
Additionally, we observed a marked increase in both precursor and OX1R mRNA within 
the hypothalamus and amygdala, respectively, following 3 cycles of sucrose binge-like drinking.  
These data suggest that hypothalamic OX neurons that project to the amygdala are involved in 
sucrose consumption.  Indeed, infusion of OX peptide directly into the amygdala greatly 
augments feeding behavior (Alò et al, 2015; Avolio et al, 2012; Rashmi et al, 2015).  
Importantly, this circuit has been specifically implicated in the consumption of highly palatable 
foods.  In fact, schedule-induced feeding of a high-sugar diet causes a robust enhancement of 
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hypothalamic prepro-orexin mRNA expression relative to a standard diet (Olszewski et al, 
2009).  Together with the data from the current study, this suggests that a hypothalamic  
amygdalar OX circuit is recruited following repeated access to highly palatable reinforcers, such 
as sucrose. 
 Findings from the present report indicate that binge-like ethanol consumption engages the 
hypothalamic OX system.  The observed reduction in hypothalamic orexin-A and -B IR from our 
IHC experiments likely reflects increased signaling.  This notion is supported by the results of 
our PCR analysis, which did not find any differences in OX mRNA due to binge-like ethanol 
consumption and suggests that the reduced levels of peptide were not a consequence of 
diminished production but rather a result of depleted peptide levels following release from the 
cell.  Moreover, we found this effect not to be specific to ethanol as binge-like sucrose drinking 
resulted in a similar pattern of effects in terms of peptide IR.  Interestingly, we found that 
repeated binge-like sucrose consumption caused a significant increase in hypothalamic prepro-
orexin and amygdalar OX1R mRNA, which supports the idea that this circuit is recruited during 
the consumption of highly palatable food.  Together, these data indicate that the OX system is 
perturbed following binge-like ethanol drinking in a DID model- specifically that binge drinking 
causes an increase in OX signaling.  Experiments in the coming chapters will examine whether 
pharmacological blockade of this apparent increase in signaling in key brain regions innervated 
by OX neurons is capable of preventing binge-like ethanol drinking behavior. 
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Figure 2.1:  The subregions of the hypothalamus investigated in the IHC experiments. 3V, third 
ventricle; D3V, dorsal third ventricle; DMH, dorsomedial hypothalamus; f, fornix; ic, internal 
capsule; LH, lateral hypothalamus; LV, lateral ventricle; mt, mammillothalamic tract; opt; optic 
tract; PFA, perifornical area of the hypothalamus; sox, supraoptic decussation. 
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Figure 2.2:  In the orexin-A IHC experiment, mice with access to ethanol bottles drank 
comparable levels of ethanol on the final day of testing regardless of whether they experienced 
one or three cycles of DID (A) and achieved similar BECs (B).  Similarly, mice that experienced 
one or three cycles of DID consumed equivalent levels of sucrose (C).  No differences were 
observed in final body mass as a function of group (D).  H2O, water group; 1E, one-cycle 
ethanol group; 3E, three-cycle ethanol group; 1S, one-cycle sucrose group; 3S three-cycle 
sucrose group.  Dashed line in (B) represents 80 mg/dl.  Data are presented as Mean ± SEM. 
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Figure 2.3:  Assessment of hypothalamic orexin-A immunoreactivity (A) revealed that, relative 
to animals with access to water (B), binge-like ethanol drinking caused a reduction in orexin-A 
levels in the LH of animals that experienced one (C) or three cycles of ethanol (D) as well as one 
(E) or three cycles of sucrose (F).  However, in the PFA, only animals that experienced three 
cycles of ethanol displayed significant reductions in levels of orexin-A while those that 
experienced one-cycle of ethanol as well as one or three cycles of sucrose exhibited no 
alterations in orexin-A IR in the PFA. LH, lateral hypothalamus; PFA, perifornical area of the 
hypothalamus; H2O, water group; 1E, one-cycle ethanol group; 3E, three-cycle ethanol group; 
1S, one-cycle sucrose group; 3S three-cycle sucrose group; * denotes p < .05 relative to H2O 
group in the same region. Horizontal white bar in B-F = 10.0 µm. Data are presented as Mean ± 
SEM. 
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Figure 2.4:  In the orexin-B IHC experiment, mice with access to ethanol bottles drank 
comparable levels of ethanol on the final day of testing regardless of whether they experienced 
one or three cycles of DID (A) and achieved similar BECs (B).  Similarly, mice that experienced 
one or three cycles of DID consumed equivalent levels of sucrose (C).  No differences were 
observed in final body mass as a function of group (D).  H2O, water group; 1E, one-cycle 
ethanol group; 3E, three-cycle ethanol group; 1S, one-cycle sucrose group; 3S three-cycle 
sucrose group.  Dashed line in (B) represents 80 mg/dl.  Data are presented as Mean ± SEM. 
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Figure 2.5:  Assessment of hypothalamic orexin-B immunoreactivity (A) revealed that, relative 
to animals with access to water (B), binge-like ethanol drinking caused a reduction in orexin-B 
levels in the LH of animals that experienced one-cycle of ethanol (C), but levels returned to 
normal in animals that went through three-cycles of ethanol DID (D).  In the PFA, a significant 
reduction in the number of orexin-B positive cells was observed in animals that experience one-
cycle of either ethanol or sucrose (E); however, peptide levels returned to normal for each of the 
three-cycle ethanol or sucrose (F) groups. LH, lateral hypothalamus; PFA, perifornical area of 
the hypothalamus; H2O, water group; 1E, one-cycle ethanol group; 3E, three-cycle ethanol 
group; 1S, one-cycle sucrose group; 3S three-cycle sucrose group; * denotes p < .05 relative to 
H2O group in the same region. Horizontal black bar in B-F = 10.0 µm. Data are presented as 
Mean ± SEM. 
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Figure 2.6:  In the PCR experiment, mice with access to ethanol bottles drank comparable levels 
of ethanol on the final day of testing regardless of whether they experienced one or three cycles 
of DID (A) and achieved similar BECs (B).  Similarly, mice that experienced one or three cycles 
of DID consumed equivalent levels of sucrose (C).  No differences were observed in final body 
mass as a function of group (D).  H2O, water group; 1E, one-cycle ethanol group; 3E, three-
cycle ethanol group; 1S, one-cycle sucrose group; 3S three-cycle sucrose group.  Dashed line in 
(B) represents 80 mg/dl.  Data are presented as Mean ± SEM. 
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Figure 2.7:  Expression of prepro-orexin within the hypothalamus (A); OX1R within the 
hypothalamus, amygdala, and VTA (B); and OX2R within the hypothalamus (C) following 
binge-like ethanol drinking.  RT-PCR analysis revealed that the three cycles of binge-like 
sucrose consumption produced a marked increase in prepro-orexin mRNA expression within the 
hypothalamus relative to all other groups except for the one-cycle ethanol group (A).  Similarly, 
the three-cycle ethanol group also showed a robust rise in OX1R mRNA expression within the 
amygdala relative to water drinking controls (B)- though no other changes in expression were 
observed in the hypothalamus or VTA.  We were only able to detect the presence of OX2R 
mRNA in the hypothalamus, but no significant alterations in expression were observed as a 
function of group (C).  H2O, water group; 1E, one-cycle ethanol group; 3E, three-cycle ethanol 
group; 1S, one-cycle sucrose group; 3S three-cycle sucrose group.  Bars that share the same 
letter are significantly different from one another (p < 0.05).  Data are presented as Mean ± SEM. 
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CHAPTER 3 
PHARMACOLOGICAL INVESTIGATION OF THE ROLE OF OREXIN SIGNALING 
WITHIN REWARD-RELATED CIRCUITRY IN BINGE-LIKE ETHANOL DRINKING 
BEHAVIOR 
Introduction 
 The OX system is comprised of two peptides, orexin-A and -B, that act on two GPCRs, 
OX1R and OX2R.  Orexin-A has been found to bind with a relatively high affinity for both 
receptors while orexin-B mainly interacts with the OX2R as it has a relatively low affinity for the 
OX1R (Sakurai et al, 1998).  Although neurons that produce the OX peptides are found 
exclusively within the hypothalamus, they project to various regions throughout the brain to 
regulate a host of neurobiological functions (Ch’ng and Lawrence, 2015; Peyron et al, 1998; 
Yoshida et al, 2005).  Indeed, relatively recent evidence has emerged that has implicated the OX 
system in modulating the responses to drugs of abuse, including ethanol (see Mahler et al, 2012 
for review). 
It was initially believed that only the OX1R would modulate ethanol responding (Harris 
and Aston-Jones, 2006) based on a limited amount of data at the time; however, later research 
revealed that the OX2R is also capable of modulating ethanol drinking (Anderson et al, 2014; 
Barson et al, 2015; Shoblock et al, 2011).  In fact, a clear pattern emerges across the literature 
that indicates that ethanol drinking parallels OX signaling such that OXR antagonists blunt 
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ethanol consumption while OXR agonists enhance drinking behavior (Jupp et al, 2011a; 
Lawrence et al, 2006; Moorman and Aston-Jones, 2009; Schneider et al, 2007). 
Despite this growing body of literature implicating the OX system in ethanol 
consumption, relatively less research has been dedicated to elucidating its role in binge-like 
ethanol drinking behavior.  Indeed, we and others have recently reported that peripheral 
administration of either an OX1R or OX2R antagonist reduces binge-like ethanol drinking using 
the “drinking in the dark” (DID) model (Anderson et al, 2014; Olney et al, 2015).   Notably, 
these investigations also found that OXR antagonists affect palatable reinforcers regardless of 
caloric content by demonstrating that these compounds also reduced binge-like sucrose 
(Anderson et al, 2014) and saccharin consumption (Alcaraz-Iborra et al, 2014; Olney et al, 
2015).  These observations indicate that peripherally administered OXR antagonists do not 
selectively modulate ethanol consumption per se, but rather regulates the underlying responses to 
general, salient reinforcers, which includes ethanol. 
These studies, however, were unable to identify the brain regions that govern this effect 
due to the systemic nature of the treatment procedure.  Considering its critical role in reward 
processing, a potential region that may play a substantial role in this effect is the VTA.  Indeed, 
engaging in reinforcing behavior has been shown to increase activity in the VTA in animals 
(Esposito et al, 1984; Porrino et al, 1984) and humans (Breiter et al, 1997) while inactivation of 
the VTA results in blunted responding to a sucrose reward (van Zessen et al, 2012).  Together, 
these studies and many others evince the VTA as a likely participant in reinforcing behavior, 
such as binge ethanol drinking. 
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What is more, the VTA is densely innervated by hypothalamic OX neurons (Ch’ng and 
Lawrence, 2015; Peyron et al, 1998; Yoshida et al, 2005) and expresses both OXR subtypes 
(Marcus et al, 2001; Narita, 2006).  OX peptides acting on either OXR subtype within the VTA 
results in a robust depolarization of VTA neurons (Korotkova et al, 2003) and is accompanied by 
a marked increase in DA release as well (España et al, 2010; Narita, 2006; Vittoz et al, 2008).  
Moreover, both orexin-A and -B have even been shown to cause plastic changes in dopaminergic 
neurons within the VTA that facilitates activity in this region (Borgland et al, 2006, 2008).  
Considering these findings, it is not surprising that infusions of a dual OXR antagonist directly 
into the VTA has been demonstrated to disrupt operant responding to ethanol in rats (Srinivasan 
et al, 2012).  As a whole, these observations implicate OX neurons- originating from the 
hypothalamus- that project to the VTA as the prime circuit that modulates binge-like ethanol 
drinking. 
 The purpose of the present study was to more definitively elucidate the contribution of 
OX signaling within the VTA in binge-like drinking behavior.  Because previous investigations 
into the role of OX signaling within the VTA in ethanol responding used a nonselective OXR 
antagonist (Srinivasan et al, 2012), we also sought to determine the individual OXR subtypes 
involved in binge drinking by utilizing selective compounds that act on either the OX1R or 
OX2R.  Here, we show that inhibition of the OX1R, but not OX2R, in the VTA selectively 
reduces binge-like ethanol drinking without altering anxiety-like behavior in the animals.  These 
data suggest that OX signaling onto OX1Rs within the VTA modulates binge-like ethanol 
drinking. 
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Methods 
Animals 
Male C57BL/6J mice (C57; Jackson Laboratories, Bar Harbor, ME), aged 6-7 weeks and 
weighing 20-25 g upon arrival, were used in each of the following studies.  Mice were 
individually housed in plastic cages located in a vivarium with an ambient temperature of 
approximately 22ºC and a reverse light/dark cycle with lights off at 8:30 am.  All animals had ad 
libitum access to food and water except when specified below.   All procedures used were in 
accordance with the National Institute of Health guidelines and were approved by the University 
of North Carolina Institutional Animal Care and Use Committee. 
Cannulation Surgery and Infusion Procedures 
Prior to testing, mice were bilaterally cannulated targeting the VTA (AP:  -3.08 mm, ML:  
±0.50 mm, DV:  -4.40 mm).  As a regional control, a separate group of mice was cannulated 
slightly dorsal to the VTA (AP:  -3.08 mm, ML:  ±0.50 mm, DV:  -3.40 mm).    Mice were given 
one week to recover from surgery before testing.  Cannula placement for each animal was 
verified histologically and animals in which the cannulas were not in the target area were 
excluded from the statistical analysis (see Figure 3.1). 
On test days, mice were infused with either the selective OX1R antagonist, SB-334867 
(SB; 0.0 or 6.0 µg; Tocris Bioscience, Bristol, UK), or the selective OX2R antagonist, TCS-
OX2-29 (TCS; 0.0, 5.0, or 7.5 µg; Tocris Bioscience, Bristol, UK).   These doses were 
determined based on what has been demonstrated to be effective previously (Borgland et al, 
2006; Li et al, 2011).  SB is 50-fold selective for the OX1R over the OX2R (Porter et al, 2001; 
Smart et al, 2001) while TCS has a 250-fold selectivity for the OX2R over the OX1R (Hirose et 
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al, 2003).  Both compounds were dissolved in dimethyl sulfoxide (DMSO) to reach the desired 
concentration.  DMSO was chosen as the solvent for both drugs in order to better equate the 
actions of SB and TCS.  Importantly, a dose higher than 7.5 µg of TCS could not be achieved 
due to restrictions in the drug’s solubility in DMSO.  All infusions were administered in a 
volume of 0.3 µl per side and were delivered over the course of one minute using an automated 
syringe pump (Harvard Apparatus, Holliston, MA). Injectors were left in the cannulae for an 
extra minute before removal to ensure adequate diffusion of the compound and to prevent reflux 
up the cannula tract.  Drug infusions for all studies were performed 30 min prior to the start of 
the behavioral test.   
Drinking in the Dark 
A cohort of 17 C57BL/6J (C57) mice was used to assess the effect of pharmacological 
inhibition of VTA OX1Rs on binge-like ethanol and sucrose consumption.  A separate group of 
22 mice was used to similarly assess inhibition of VTA OX2Rs.  Additionally, another cohort of 
12 mice was used to verify the specificity of the effect by infusing the OX1R antagonist into a 
control region 1.0 mm dorsal to the VTA.  The DID procedure is a commonly used animal model 
of binge-like ethanol drinking that promotes high levels of consumption and generates 
physiologically relevant blood ethanol concentrations (BECs) of 80 mg/dl or greater (Rhodes et 
al, 2005, 2007). On days 1-3, standard water bottles were removed three hours into the dark 
cycle and the animals were given access to a single test bottle containing ethanol (20% v/v) or 
sucrose (3% w/v) solutions for two hours.  Binge-like intake was assessed on the fourth day in 
which test bottles were measured hourly in order to examine the effect of the drug on 
consumption over time.  Immediately after test bottles were removed on the fourth day of ethanol 
testing, tail-blood samples were taken from each animal and processed to determine blood 
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ethanol concentration (BEC) using an alcohol analyzer (Analox Instruments, London, UK). A 
two hour test period was chosen as we have previously had success capturing the transient 
effects of the drug using this shortened procedure (Olney et al, 2015).  In order to increase power 
during statistical analysis, a Latin-square design was used such that each animal received all 
doses of the drug over repeated trials.  Mice were given three days of rest between subsequent 4-
day DID sessions in order to avoid carryover effects of the drug.   
Elevated Zero Maze 
A separate cohort of 12 C57s was used to assess the effect of pharmacological inhibition 
of VTA OX1Rs on anxiety-like behavior using a five minute test on the elevated zero maze 
(Med Associates, Inc., St. Albans, VT).  The elevated zero maze is a common tool used among 
investigators in order to assess anxiety-like behavior.  Here, anxiolytic drugs increase the amount 
of time spent in the open area while anxiogenic drugs increase the amount of time spend in the 
closed areas (Shepherd et al, 1994).  One hour before testing, animals were brought into a dark 
room that housed the elevated zero maze.  Approximately three hours into the dark cycle, testing 
on the elevated zero maze began by placing the animal in the open area of the maze.  Each 
session was recorded using a camcorder placed above the apparatus and was scored by an 
investigator blind to the animal’s group assignment who recorded the time (s) spent in the open 
area as well as the number of entries into the open and closed area.  The animal was considered 
to have entered the open area when all four paws left the closed area.  Open area time was 
considered terminated once all of the animal’s paws entered the closed area.  We also assessed 
the number of instances and time (s) spent “exploring” the open area from the closed area.  
Exploring behavior was defined as each time the animal, while still in the closed area, extended 
its head beyond the ears into the open area.  Exploring behavior ceased when the animal either 
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entered the open area or retreated back into the closed area.  Animals were returned to their 
homecage immediately after the conclusion of the test session.  Unlike DID testing, a Latin-
square design was not used in order to avoid previous experience with the apparatus confounding 
the animals’ behavior.  Treatment groups were equated based on body weight and each animal 
received a single, bilateral infusion of either 0.0 or 6.0 µg of SB. 
Open-Field Locomotor Activity 
The same group of animals from the previous elevated zero maze test was used to assess 
the effect of pharmacological inhibition of VTA OX1Rs on locomotor activity; however, one 
animal’s cannula became clogged in the interim time between tests and was unable to be infused.  
Thus, only 11 C57s were used.  In addition to assessing general locomotor activity in the 
animals, this test is capable of measuring anxiety-like behavior as well.  Similar to the elevated 
zero maze, treatment with anxiolytic compounds generally causes the animal to increase the 
amount of time spent in the center of the open-field chamber (Choleris et al, 2001).  Testing in 
the open-field locomotor chambers occurred 48 h after testing in the elevated zero maze.  One 
hour before testing, animals were brought into a dark room adjacent to the room that housed the 
locomotor chambers.   Three hours into the dark cycle, animals were placed in a 16.5 x 16.5 in
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open-field locomotor chamber (Accuscan Instruments, Columbus, OH) and locomotor activity 
was recorded in five minute bins for one hour using VersaMax software (Omnitech Electronics, 
Columbus, OH).  This software was able to record total distance traveled (cm) as well as the time 
(s) spent and distance traveled (cm) in the center or margin of the chamber.  Using these 
measures, we calculated separate variables for the percent time spent in the center of the chamber 
([time spent in the center ÷ (time spent in the center + time spent in the margins)] × 100) as well 
as the percent distance traveled in the center of the chamber ([distance traveled in the center ÷ 
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(distance traveled in the center + distance traveled in along the margins)] × 100).  Mice were 
placed back into their homecages after the one hour test period.  Like the elevated plus maze, a 
Latin-square design was not used for the locomotor test.  Animals received a single, bilateral 
infusion of either 0.0 or 6.0 µg of SB.  Each animal received the alternate drug treatment based 
on its assigned drug condition during the previous elevated zero maze test. 
Data Analysis 
A repeated-measures ANOVA was used to assess hourly binge consumption with both 
time (hour 1 and hour 2) and dose (0.0 or 6.0 µg for SB; 0.0, 5.0, or 7.5 µg for TCS) being 
within-subject variables.  Additionally, BEC and total binge consumption across the two-hour 
test period was assessed using separate repeated-measures ANOVAs with dose (0.0 or 6.0 µg for 
SB; 0.0, 5.0, or 7.5 µg for TCS) as the within-subject variable.  We also included drug order as a 
between-subjects variable in these analyses to ensure the order in which the animals were 
presented the drug did not have any confounding effects on drinking behavior.  Importantly, due 
to the relatively short half-life and hyper-transient nature of the compounds (Mould et al, 2014; 
Porter et al, 2001), the effects of these compounds can be rather short-lived (Olney et al, 2015). 
Thus, planned comparisons were used to assess binge-like consumption of each drug group 
relative to its respective vehicle during the first hour of testing in order to better capture the 
short-lived effect of the compound.   
Additionally, separate univariate ANOVAs used dose of SB (0.0 or 6.0 µg) to predict the 
time spent in the open area, the number of entries into the open area, time spent exploring the 
open area, and frequency of exploratory behavior in the elevated plus maze paradigm. Similarly, 
separate repeated-measures ANOVAs were used to assess behavior in the open-field locomotor 
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tests with dose of SB (0.0 or 6.0 µg) being a between-subjects variable while total distance 
traveled, percent distance traveled in the center, and percent time spent in the center across the 
twelve 5-min bins were all considered within-subject variables.  Tukey’s LSD post-hoc tests and 
Bonferroni corrections were employed throughout the analyses when applicable.   
Results 
Our omnibus analysis revealed that binge-like ethanol consumption levels did not change 
over time (Figure 3.2A; Main effect of Time:  F(1,15) = 2.701, p = 0.121) nor did inhibition of 
OX1Rs in the VTA significantly alter binge-like ethanol drinking (Main effect of Dose:  F(1,15) = 
2.651, p = 0.096; Time×Dose Interaction:  F(1,15) = 2.189, p = 0.160).  However, planned 
comparisons revealed that, relative to vehicle treated controls, SB significantly blunted binge-
like ethanol intake during the first hour of testing (t(16) = 2.208, p = 0.042).  Moreover, no 
significant effect was observed in total binge-like ethanol drinking across the two-hour test 
period (F(1,15) = 3.161, p = 0.096).  Despite the reduction in binge drinking during the first hour 
of testing, no significant difference in BECs was observed between the two drug conditions 
when blood samples were collected after the full two hour test (Figure 3.2B; F(1,15) = 0.419, p = 
0.527).  Importantly, binge-like ethanol drinking was not affected by the order in which the 
animals received their treatment (F(1,15) = 3.489, p = 0.081) nor did it impact BECs (F(1,15) = 
0.134, p = 0.720). 
 Looking next at binge-like sucrose consumption, there was a trend for animals to 
consume more sucrose during the first hour of testing relative to the second but the effect did not 
reach significance (Figure 3.2C; Main effect of Time:  F(1,15) = 4.253, p = 0.064).  Binge-like 
sucrose drinking was not impacted as a function of SB treatment (Main effect of Dose:  F(1,15) = 
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0.711, p = 0.412); however, we did find a significant interaction effect (Time×Dose Interaction:  
F(1,15) = 4.876, p = 0.043).  Further probing revealed that this effect was driven by the fact that 
binge-like sucrose intake among vehicle-treated animals was significantly greater during the first 
hour of testing relative to the second hour (t(16) = 2.473, p = 0.025).  Notably, planned 
comparisons revealed no significant difference in sucrose consumption during the first hour of 
testing between the two treatment groups (t(16) = 1.463, p = 0.163).  Moreover, sucrose 
consumption across the entire two hour test period did not significantly vary as a function of SB 
treatment (F(1, 15) = 0.711, p = 0.412).  Additionally, the order in which the animal received the 
compound did not confound binge-like sucrose drinking (F(1, 15) = 0.024, p = 0.878). 
 Importantly, we found the effect of intra-VTA SB to blunt binge-like ethanol 
consumption to be specific to the VTA as similar treatment slightly dorsal to the VTA did not 
produce any significant alterations in binge-like ethanol drinking as a function of treatment 
(Figure 3.2D; Main effect of Dose:  F(1,10) = 4.188, p = 0.068; Time×Dose Interaction:  F(1,10) = 
3.989, p = 0.074; Total ethanol consumption:  F(1,10) = 4.188, p = 0.068; SB versus vehicle 
planned comparison at the first hour:  t(11) = -0.278, p = 0.786) although we did observe that the 
animals drank significantly more ethanol during the second hour of testing relative to the first 
hour regardless of treatment condition (Main effect of Time:  F(1,10) = 7.037, p = 0.024).  
Moreover, we did not observe any effect on BEC levels as a function of treatment (Figure 3.2E; 
F(1,9) = 0.028, p = 0.870).  Additionally, whether the animal received treatment with vehicle or 
SB first did not impact binge-like ethanol consumption (F(1,10) = 0.268, p = 0.616) or BECs (F(1,9) 
= 0.108, p = 0.750). 
 We next sought do determine the role of intra-VTA OX2Rs in binge-like ethanol 
drinking.  Repeated-measures ANOVA revealed that there was a marginal effect of ethanol 
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drinking over time but the effect did not reach significance (Figure 3.3A; Main effect of Time:  
F(1,19) = 3.175, p = 0.091).  Similarly, none of the doses tested affected binge-like ethanol intake 
(Main effect of Dose:  F(2,38) = 0.669, p = 0.518; Time×Dose Interaction:  F(2,38) = 0.425, p = 
0.657).  Using planned comparisons, we did not observe any significant effect in the low dose 
(5.0 µg) of TCS relative to vehicle-treated controls during the first hour of testing (t(21) = -0.005, 
p = 0.996) but we did see a marginal, yet nonsignificant, trend for the high dose (7.5 µg) of TCS 
to reduce binge-like ethanol consumption relative to vehicle (t(21) = 1.790, p = 0.088).  
Additionally, we did not observe any effect across the total two hours of testing (F(2,38) = 0.669, p 
= 0.518). Although we did not observe any significant alterations in drinking behavior, there was 
a marginal, albeit nonsignificant, effect for BEC levels to vary as a function of treatment group 
(Figure 3.3B; F(2,34) = 3.181, p = 0.054).  Moreover, the order in which the animals received the 
drug treatment did not significantly impact binge-like ethanol drinking (F(1, 19) = 0.194, p = 
0.825). 
 It is well-known that both positive and negative reinforcement may drive an individual to 
consume ethanol (Eckardt et al, 1998; Koob, 2009; Sinha, 2007).  The VTA is perhaps best 
known as a brain area that is integral to reward processing; however, recent evidence has 
emerged that indicates that OX activity in the VTA may drive stress responding as well (Hata et 
al, 2011).  In an effort to disentangle the overlaying psychological drive that explains how 
inhibition of OX1Rs in the VTA ultimately leads to blunted binge-like ethanol drinking we next 
sought to explore how intra-VTA treatment with SB affects anxiety-like behavior.  Using the 
elevated zero maze, we found that silencing signaling onto OX1Rs within the VTA did not alter 
the time spent in the open area (Figure 3.4A; F(1, 10) = 1.169, p = 0.305) or the number entries 
into the open area (Figure 3.4B; F(1, 10) = 0.002, p = 0.964).  What is more, the drug impacted 
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neither the frequency that the animal explored the open area (Figure 3.4D; F(1, 10) = 1.901, p = 
0.198) nor the time engaged in exploratory behavior (F(1, 10) = 1.443, p = 0.257). 
       Similarly, we did not observe any effect of intra-VTA SB on anxiety-like behaviors as 
measured in the open-field locomotor test.  Inhibiting OX1Rs within the VTA did not alter the 
proportion of distance traveled in the center of the chamber relative to the margins (Figure 3.5A; 
Main effect of Dose:  F(1, 8) =  0.740, p = 0.415; Time×Dose Interaction:  F(11,88) = 1.425, p = 
0.254); although the animals did display significant variability in the proportion of distance 
traveled in the center as a function of time (Main effect of Time:  F(11,88) =  4.573, p = 0.007).  
Further probing of this effect with Tukey’s LSD revealed the significant differences at the 
following time points:  10 min > 40 min (p = 0.002), 10 min > 55 min (p = 0.001), 15 min > 25 
min (p = 0.002), 15 min > 55 min (p = 0.003), 20 min > 55 min (p = 0.003), 35 min > 45 min (p 
= 0.002), 35 min > 50 min, (p = 0.004), 35 min > 55 min (p = 0.001).  We also did not observe 
any significant effects in any of the variables assessing the proportion of time spent in the center 
of the chamber relative to the margins (Figure 3.5B; Main effect of Time:  F(11,88) =  1.223, p = 
0.318; Main effect of Dose:  F(1, 8) =  0.156, p = 0.704; Time×Dose Interaction:  F(11,88) = 0.700, p 
= 0.617).  Notably, intra-VTA treatment with SB did not significantly influence gross locomotor 
activity (Figure 3.5C; Main effect of Dose:  F(1, 8) =  2.122, p = 0.183; Time×Dose Interaction:  
F(11,88) = 1.472, p = 0.231); although the animals exhibited varying amounts of activity across the 
60 min test period (Main effect of Time:  F(11,88) =  10.544, p < 0.0001).  Post hoc analyses of 
this effect revealed that the animals were most active towards the beginning of the test (5 min > 
all other time points, p’s < 0.002; 10 min > 20 min, p = 0.001; 10 min > 60 min, p = 0.004). 
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Discussion 
It has previously been reported that peripheral administration of either an OX1R or 
OX2R antagonist is capable of protecting against binge-like consumption of a salient reinforcer 
(Anderson et al, 2014; Olney et al, 2015), and that signaling onto the OX1R or OX2R (or both) 
within the VTA modulates ethanol responding (Srinivasan et al, 2012).  Findings from the 
current report were able to provide a more detailed characterization of the contribution of OX 
signaling within the VTA in modulating binge-like ethanol drinking behavior.  Specifically, we 
demonstrated that intra-VTA infusion of SB, but not TCS, reduced binge-like ethanol intake.  
Despite this effect, SB did not significantly reduce BECs; however, this may be due to the very 
short half-life (Porter et al, 2001) and the fact that BECs were measured at the end of the two 
hour test period. Moreover, this effect was found to be reinforcer- and brain region-specific as 
similar treatment with SB did not alter binge-like sucrose consumption nor did it impact binge-
like ethanol drinking when infused dorsal to the VTA.  Notably, inhibiting OX1Rs in the VTA 
did not impact general locomotor behavior (Figure 3.5C)-indicating that such treatment does not 
engage OX circuitry involved in sleep and arousal (de Lecea, 2012).  Together, these 
experiments were able to extend the previous literature by observing OX signaling- specifically 
onto the OX1R- within the VTA, in part, modulates binge-like ethanol consumption without 
altering anxiety-like behaviors. 
Notably, inhibiting intra-VTA OX2Rs via TCS failed to significantly alter binge-like 
ethanol drinking in our experiments across a range of doses.  Although one may surmise that- 
based on our findings- OX2Rs within the VTA do not contribute to binge drinking behavior, it 
may be more appropriate to conclude that OX2Rs play a subsidiary role to OX1Rs in modulating 
ethanol drinking.  Indeed, previous studies have demonstrated that the OX2R is capable of 
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modulating ethanol drinking (Anderson et al, 2014; Barson et al, 2015; Shoblock et al, 2011).  
More importantly, we did observe a slight, albeit nonsignificant, trend for the higher dose of TCS 
(7.5 µg) to disrupt ethanol drinking during the first hour of testing relative to vehicle-treated 
animals.  Furthermore, we also observed that the lower dose of TCS (5.0 µg) reduced BECs to a 
level below the threshold to be considered a binge episode and marginally reduced BECs relative 
to vehicle-treated controls.  Together, these findings suggest that OX2Rs in the VTA may have 
relatively more subtle effects on ethanol consumption that were not fully captured in the present 
experiments.  Thus, it may be the case that signaling onto OX2Rs within the VTA contributes to 
binge-like ethanol drinking behavior but that its role is secondary to that of OX1Rs- although 
further testing of this hypothesis is needed before any definitive conclusions can be drawn.  
Although we used a range of doses in order to better assess the contribution of the OX2R, we 
were limited in the concentration of TCS we could feasibly use due to restrictions in the 
solubility of the compound in DMSO; thus, alternative OXR agents may be ideal for future 
investigations.  For example, if the OX2R does contribute to this behavior then intra-VTA 
administration of orexin-B, which has a much greater affinity for the OX2R over the OX1R, may 
augment ethanol drinking behavior. 
 Perhaps the most intriguing observation was the fact that the reduction in binge-like 
drinking produced by intra-VTA treatment with SB was selective for ethanol intake.  Contrary to 
the present results, numerous studies have reported that the effects of OXR antagonists are not 
specific to ethanol but rather more broadly affect responding to general, salient reinforcers 
(Alcaraz-Iborra et al, 2014; Anderson et al, 2014; Olney et al, 2015).  This is not the first 
instance in which differential effects of OXR antagonists on responding to reinforcers has been 
observed as OXR antagonists have been shown to reduce operant responding to ethanol, but not 
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sucrose (Jupp et al, 2011a; Srinivasan et al, 2012).  The ability of drugs of abuse to produce a 
rewarding experience in the organism is commonly conceptualized as being due to its ability to 
“hijack” the brain’s existing natural reward system.  In this sense, there is a great deal of overlap 
regarding the circuitry regulating natural rewards and that which modulates drugs of abuse.  
However, our findings and others suggest that a distinct OX circuit- likely involving the VTA- is 
recruited for ethanol consumption versus that of a natural reward.  As a whole, these discoveries 
reveal that these pathways may be more segregated than originally believed- a notion that may 
hold great value when developing novel treatments for drug abuse. 
 Although it has been long-known that ethanol activates these reward circuits (Ingvar et 
al, 1998; Weiss et al, 1993), ethanol also engages stress/anxiety circuits to produce anxiolysis 
(Barkley-Levenson and Crabbe, 2015; Pandey et al, 2008; Wilson et al, 2004).   Considering that 
both the positive- and negative-reinforcing effects of ethanol’s neurobiological actions may serve 
to perpetuate drinking (Eckardt et al, 1998) and intra-VTA OX signaling modulates both reward 
processing (Taslimi et al, 2012) and stress responding (Hata et al, 2011), it was necessary to 
elucidate whether the effects observed in the present report were associated with alterations in 
stress responses, such as anxiety-like behavior.  Results garnered from the current experiments 
revealed that intra-VTA SB does not impact anxiety-like behaviors as measured in either the 
elevated zero maze or open-field locomotor tests, suggesting that suppression of OX1R 
signaling, at least within the VTA, does not alter stress responding. Accordingly, these data 
suggest that OX1R inhibition in the VTA blunts binge-like ethanol drinking independent of 
changes in anxiety-like behaviors. 
 In summary, findings from the present report suggest that OX1R signaling within the 
VTA, in part, regulates binge-like ethanol consumption. Further, the lack of an effect observed 
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following site-specific TCS infusion suggests that OX2R signaling in the VTA may not 
significantly contribute to binge drinking behavior. Interestingly, although peripheral SB blunts 
binge-like consumption of a palatable reinforcer (Alcaraz-Iborra et al, 2014; Anderson et al, 
2014; Olney et al, 2015), intra-VTA infusion of SB did not alter sucrose intake- suggesting that a 
distinct OX circuit is recruited for ethanol consumption versus a natural reward.  What is more, 
the fact that these manipulations did not impact anxiety-like behavior suggests that OX1R 
antagonists protect against binge-like ethanol drinking independent of effects on anxiety-like 
behaviors.  Together, these findings provide further support that OXR antagonists may be 
promising targets for treating alcohol use disorders (Khoo and Brown, 2014).  Indeed, a 
pharmacotherapy that is effective in curbing ethanol drinking while leaving responding to natural 
reinforcers intact- as these data suggest OX1R antagonists are capable of- is certainly an 
appealing quality and should be further explored. 
 
  
57 
 
Figure 3.1:  Cannula placements for the studies that examined pharmacological inhibition of 
OX1Rs in the VTA via SB on binge-like ethanol and sucrose (A) consumption, inhibition of 
OX2Rs in the VTA via TCS on binge-like ethanol consumption (B), the effect of intra-VTA SB 
administration on anxiety-like behavior (C), and the site-control study that infused SB dorsal to 
the VTA (D).  Following histological assessment of cannula placement, it was determined that 
two subjects from the SB-VTA ethanol and sucrose studies, three from the TCS-VTA ethanol 
study, and three for the SB-VTA anxiety-like behavior studies were needed to be excluded due to 
poor cannula placement.  Each filled circle represents the location of a cannula in the target 
region. 
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Figure 3.2:  Inhibition of OX1Rs in the VTA selectively reduces binge-like ethanol 
consumption.  Animals infused with SB directly into the VTA exhibited blunted binge-like 
ethanol consumption relative to vehicle-treated controls but only during the first hour of testing 
(A).  Despite this reduction in consumption, no significant effect was observed in BECs as 
measured at the end of the two hour test period (B).  Interestingly, intra-VTA infusion of SB did 
not significantly affect binge-like sucrose consumption at any point during the test (C) though a 
significant Time×Dose interaction revealed that vehicle-treated animals drank significantly more 
sucrose during the first hour of testing relative to the second.   Importantly, this phenomenon was 
specific to the VTA treatment as SB infused directly dorsal to the VTA did not significantly 
impact binge-like ethanol drinking (D) or subsequent BECs (E) at the end of the two hour test 
period.  We did, however, observe that animals drank significantly more ethanol during the 
second hour of testing relative to the first hour regardless of treatment group. * denotes that p < 
0.05 relative to vehicle-treated animals during the first hour of testing.  † signifies that p < 0.05 
relative to vehicle-treated animals during the first hour of testing.  # denotes that animals drank 
significantly more during the second hour of testing relative to the first hour regardless of 
treatment group.  Dotted line in (B) delineates 80 mg/dl, the minimum BEC to constitute a binge 
episode.  Data presented as Mean ± SEM. 
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Figure 3.3:  Inhibition of OX2Rs in the VTA does not significantly alter binge-like 
consumption.  Infusion of TCS into the VTA does not significantly impact binge-like ethanol 
consumption at any point throughout the test period (A) nor does it significantly alter observed 
BEC levels (B).  Dotted line in (B) delineates 80 mg/dl.  Data presented as Mean ± SEM. 
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Figure 3.4:  The effect on intra-VTA infusion of SB on anxiety-like behavior as measured via 
the elevated plus maze.  Relative to treatment with vehicle, inhibition of OX1Rs within the VTA 
does not significantly alter time spent in the open area (A), the number of entries into the open 
area (B), or the number and duration of exploration behaviors (C; left and right axes, 
respectively).  Data presented as Mean ± SEM. 
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Figure 3.5:  Inhibition of VTA OX1Rs via site-directed infusion of SB does not alter behavioral 
measures using the open-field locomotor assay.  Relative to treatment with vehicle, suppression 
of activity onto the OX1R within the VTA does not affect measures of anxiety-like behavior:  
percent distance traveled in the center of the chamber (A) or the percent time spent in the center 
(B).  Additionally, relative to vehicle-treated controls, animals infused with SB do not display 
detriments in locomotor behavior (C).  Data presented as Mean ± SEM. 
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CHAPTER 4 
PHARMACOLOGICAL INVESTIGATION OF THE ROLE OF OREXIN SIGNALING 
WITHIN STRESS-RELATED CIRCUITRY IN BINGE-LIKE ETHANOL DRINKING 
BEHAVIOR 
Introduction 
Alcohol abuse is a serious health concern that affects individuals across a wide range of 
social strata (Naimi et al, 2003).  Not surprisingly, alcohol abuse remains a leading cause of 
preventable death (Mokdad et al, 2004) and inflicts especially high social and economic costs on 
society (Bouchery et al, 2011; Sacks et al, 2015).  As such, the development of effective 
treatment strategies that address this destructive behavior has the potential to have a major 
positive impact on society.  Therefore, a better understanding of the biological mechanisms that 
modulate binge drinking behavior may be beneficial in facilitating the development of novel 
treatments for alcohol use disorders (AUDs).   
One such mechanism that has been implicated in ethanol responding is the orexin (OX) 
system (see Lawrence, 2010 for review).  Neurons that produce the OX peptides, orexin-A and -
B, are highly localized within the hypothalamus yet project to numerous regions throughout the 
brain.  These OX projection fibers release OX on to two G-protein coupled receptors, orexin-1 
and orexin-2 receptors (OX1R and OX2R, respectively), to regulate a myriad of physiological 
functions including feeding (Sakurai et al, 1998), sleep (Chemelli et al, 1999), reward (Harris et 
al, 2005), and stress (Kuru et al, 2000).  These latter two functions are of particular interest as 
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both positive- and negative-reinforcement are known to provide substantial impetus to drink 
ethanol (Eckardt et al, 1998; Ray et al, 2009). 
The previous chapter demonstrated that inhibiting the OX1R in the ventral tegmental area 
(VTA) did not alter anxiety-like behavior; thus, blocking OX1R signaling, at least within in the 
VTA, modulates binge-like ethanol drinking independent of modulation of anxiety-like behavior.  
However, the VTA plays a relatively minor role in stress responding.  In order to better elucidate 
the contribution of OX stress circuitry in binge drinking behavior, it is necessary to further 
investigate other brain regions that are more critically involved in stress and anxiety, such as the 
amygdala. 
 The amygdala is comprised of several subnuclei, among them the central nucleus of the 
amygdala (CeA) and basolateral amygdala (BLA), and is critically involved in emotional 
processing (see Janak and Tye, 2015 for review).  Anatomical mapping studies that assessed 
immediate-early gene expression as a measure for neuronal activity have reported that both the 
BLA and CeA are engaged following ethanol administration in mice (Bachtell et al, 1999; 
Bachtell and Ryabinin, 2001); however, Pandey and colleagues (2008) observed signs of 
synaptic plasticity in the CeA, but not BLA, following acute ethanol administration- suggesting a 
more pivotal role for the CeA in neurobiological responses to ethanol.  Further, the CeA has also 
been implicated in the expression of ethanol-induced anxiolysis (Pandey et al, 2008; Sharko et 
al, 2015).   
What is more, previous investigations have reported rather dense orexinergic projections 
terminating in the CeA while relatively fewer fibers project to the BLA (Nambu et al, 1999; 
Peyron et al, 1998; Schmitt et al, 2012).  Indeed, application of both orexin-A and -B results in a 
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robust depolarization of CeA neurons in vitro (Bisetti et al, 2006; Winsky-Sommerer et al, 2004) 
and central administration of OX in vivo engages neurons within the CeA (Hata et al, 2011; 
Sakamoto et al, 2004).  Taken together, these findings suggest that OX input onto the CeA may 
modulate binge-like ethanol drinking secondarily through modulation of stress responses, 
consistent with the idea that ethanol consumption may be reinforced, in part, via stress reduction. 
In addition to modulating stress processing, findings from multiple lines of research 
implicate the CeA as a key modulator of reward processing.  In fact, the CeA is considered part 
of the mesolimbic reward circuit and sends projections to both the VTA (Zahm et al, 1999) and 
nucleus accumbens (Vertes et al, 2012).  Indeed, optogentic stimulation of neurons within the 
CeA greatly enhances motivation towards a reward-paired cue (Robinson et al, 2014).  
Moreover, the actions of a litany of other peptides, such as neurotensin (László et al, 2010), 
oxytocin (László et al, 2016), and substance P (Kertes et al, 2009), within the CeA have also 
been demonstrated to modulate reward-related behaviors.  Furthermore, it has previously been 
demonstrated that administration of a positive modulator of AMPA receptors in the CeA 
increased operant responding for ethanol  (Cannady et al, 2016).  Together, these data indicate 
that the CeA is involved in reward-related processing in addition to stress responding. 
The goal present chapter was to characterize the contribution OXR signaling within the 
CeA in modulating binge-like ethanol drinking.  To ascertain whether modulation of binge-like 
ethanol drinking is associated with modulation of anxiety-like behavior, we also tested the effect 
of intra-CeA OXR inhibition on anxiety-like behaviors.  As predicted, inhibiting OX signaling 
within the CeA successfully attenuated binge-like ethanol drinking.  More specifically, local 
infusions of either an OX1R or OX2R antagonist into the CeA reduced ethanol, but not sucrose, 
intake.  Additionally, we also observed that similar inhibition of OX1Rs in the neighboring BLA 
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did not affect binge-like ethanol or sucrose drinking.  Inconsistent with our predictions, however, 
was the fact that blocking OX1R signaling in the CeA did not impact anxiety-like behaviors in 
either the elevated zero maze or open-field locomotor chamber.  Together, these findings 
indicate that OXR signaling in the CeA participates in binge ethanol drinking and suggests that 
this region may modulate this behavior by altering the positive-reinforcing, rather than negative-
reinforcing, consequences of ethanol consumption. 
Methods 
Animals 
Male C57BL/6J mice (C57; Jackson Laboratories, Bar Harbor, ME), aged 6-7 weeks and 
weighing 20-25 g upon arrival, were used in each of the following studies.  Mice were 
individually housed in plastic cages located in a vivarium with an ambient temperature of 
approximately 22ºC and a reverse light/dark cycle with lights off at 8:30 am.  All animals had ad 
libitum access to food and water except when specified below.   All procedures used were in 
accordance with the National Institute of Health guidelines and were approved by the University 
of North Carolina Institutional Animal Care and Use Committee. 
Cannulation Surgery and Infusion Procedures 
Prior to testing, mice were bilaterally cannulated targeting the CeA (AP:  -1.06 mm, ML:  
±2.35 mm, DV:  -4.50 mm).  An additional cohort of animals was bilaterally cannulated 
targeting the BLA (AP:  -1.22 mm, ML:  ±3.01 mm, DV:  -4.74 mm) as a region-specific control.    
Mice were given one week to recover from surgery before testing.  Cannula placement for each 
animal was verified histologically and animals in which the cannulas were not in the target area 
were excluded from the statistical analysis (see Figure 4.1). 
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On test days, mice were infused with either the selective OX1R antagonist, SB-334867 
(0.0 or 6.0 µg; Tocris Bioscience, Bristol, UK), or the selective OX2R antagonist, TCS-OX2-29 
(0.0 or 7.5 µg; Tocris Bioscience, Bristol, UK).  These compounds are 50- and 250-fold, 
respectively, selective for their respective OXR target over the other subtype (Hirose et al, 2003; 
Porter et al, 2001; Smart et al, 2001).   The decision to use only the higher dose (7.5 µg) of TCS 
was due to the fact that we did not observe any significant effects of the lower dose (5.0 µg) 
from our previous investigations in the VTA (see Chapter 3). Both compounds were dissolved in 
dimethyl sulfoxide (DMSO) to reach the desired concentration.  All infusions were administered 
in a volume of 0.3 µl per side and were delivered over the course of one minute using an 
automated syringe pump (Harvard Apparatus, Holliston, MA).  Injectors were left in the 
cannulae for an extra minute before removal to ensure adequate diffusion of the compound and 
to prevent reflux up the cannula tract.  Drug infusions for all studies were performed 30 min 
prior to the start of the behavioral test.   
Drinking in the Dark 
A cohort of 15 C57s was used to assess the effect of pharmacological inhibition of CeA 
OX1Rs on binge-like consumption.  However, the cannula of one animal became clogged 
following ethanol DID testing; therefore, only 14 C57s were used in the intra-CeA sucrose DID 
test.  This same group of mice was also used to similarly assess inhibition of CeA OX2Rs.  
Additionally, another cohort of 13 mice was used to investigate the site-specificity of this effect 
by assessing binge-like ethanol consumption following local infusion into the BLA.  The DID 
procedure is a commonly used animal model of binge-like ethanol drinking that promotes high 
levels of consumption and generates physiologically relevant blood ethanol concentrations 
(BECs) of 80 mg/dl or greater (Rhodes et al, 2005, 2007). On days 1-3, standard water bottles 
68 
 
were removed three hours into the dark cycle and the animals were given access to a single test 
bottle containing ethanol (20% v/v) or sucrose (3% w/v) solutions for two hours.  Binge-like 
intake was assessed on the fourth day in which test bottles were measured hourly in order to 
examine the effect of the drug on consumption over time.  Immediately after test bottles were 
removed on the fourth day of ethanol testing, tail-blood samples were taken from each animal 
and processed to determine BEC.  As with the previous chapter, a shortened test period was 
chosen in order to better capture the transient effects of the compounds.  In order to increase 
power during statistical analysis, a Latin-square design was used such that each animal received 
all doses of the drug over repeated trials.  Mice were given three days of rest between subsequent 
4-day DID sessions in order to avoid carryover effects of the drug.   
Elevated Zero Maze 
The same mice used to investigate the contribution of OX1R signaling on binge-like 
consumption were also used assess the effect of pharmacological inhibition of CeA OX1Rs on 
anxiety-like behavior using a five minute test on the elevated zero maze (Med Associates, Inc., 
St. Albans, VT).  The elevated zero maze is a common tool used among investigators in order to 
assess anxiety-like behavior.  Here, anxiolytic drugs increase the amount of time spent in the 
open area while anxiogenic drugs increase the amount of time spend in the closed areas 
(Shepherd et al, 1994).  One hour before testing, animals were brought into a dark room that 
housed the elevated zero maze.  Approximately three hours into the dark cycle, testing on the 
elevated zero maze began by placing the animal in the open area of the maze.  Each session was 
recorded using a camcorder placed above the apparatus and was scored by an investigator blind 
to the animal’s group assignment who recorded the time (s) spent in the open area as well as the 
number of entries into the open and closed area.  The animal was considered to have entered the 
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open area when all four paws left the closed area.  Open area time was considered terminated 
once all of the animal’s paws entered the closed area.  We also assessed the number of instances 
and time (s) spent “exploring” the open area from the closed area.  Exploring behavior was 
defined as each time the animal, while still in the closed area, extended its head beyond the ears 
into the open area.  Exploring behavior ceased when the animal either entered the open area or 
retreated back into the closed area.  Animals were returned to their homecage immediately after 
the conclusion of the test session.  Unlike DID testing, a Latin-square design was not used in 
order to avoid previous experience with the apparatus confounding the animals’ behavior.  
Treatment groups were equated based on body weight and each animal received a single, 
bilateral infusion of either 0.0 or 6.0 µg of SB. 
Open-Field Locomotor Activity 
The same group of animals from the previous elevated zero maze test was used to assess 
the effect of pharmacological inhibition of CeA OX1Rs on locomotor activity; however, one 
animal’s cannula became clogged in the interim time between tests and was unable to be infused.  
Thus, only 14 C57s were used.  In addition to assessing general locomotor activity in the 
animals, this test is capable of measuring anxiety-like behavior as well.  Similar to the elevated 
zero maze, treatment with anxiolytic compounds generally causes the animal to increase the 
amount of time spent in the center of the open-field chamber (Choleris et al, 2001).  Testing in 
the open-field locomotor chambers occurred 48 h after testing in the elevated zero maze.  One 
hour before testing, animals were brought into a dark room adjacent to the room that housed the 
locomotor chambers.   Three hours into the dark cycle, animals were placed in a 16.5 x 16.5 in
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open-field locomotor chamber (Accuscan Instruments, Columbus, OH) and locomotor activity 
was recorded in five minute bins for one hour using VersaMax software (Omnitech Electronics, 
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Columbus, OH).  This software was able to record total distance traveled (cm) as well as the time 
(s) spent and distance traveled (cm) in the center or margin of the chamber.  Using these 
measures, we calculated separate variables for the percent time spent in the center of the chamber 
([time spent in the center ÷ (time spent in the center + time spent in the margins)] × 100) as well 
as the percent distance traveled in the center of the chamber ([distance traveled in the center ÷ 
(distance traveled in the center + distance traveled in along the margins)] × 100).  Mice were 
placed back into their homecages after the one hour test period.  Like the elevated plus maze, a 
Latin-square design was not used for the locomotor test.  Animals received a single, bilateral 
infusion of either 0.0 or 6.0 µg of SB.  Each animal received the alternate drug treatment based 
on its assigned drug condition during the previous elevated zero maze test. 
Data Analysis 
A repeated-measures ANOVA was used to assess hourly binge-like consumption with 
both time (hour 1 and hour 2) and dose (0.0 or 6.0 µg for SB; 0.0 or 7.5 µg for TCS) being 
within-subject variables.  Additionally, BEC and total binge consumption across the two-hour 
test period was assessed using separate repeated-measures ANOVAs with dose (0.0 or 6.0 µg for 
SB; 0.0 or 7.5 µg for TCS) as the within-subject variable.  We also included drug order as a 
between-subjects variable in these analyses to ensure the order in which the animals were 
presented the drug did not have any confounding effects on drinking behavior. Importantly, due 
to the relatively short half-life and hyper-transient nature of the compounds (Mould et al, 2014; 
Porter et al, 2001), the effects of these compounds can be rather short-lived (Olney et al, 2015). 
Thus, planned comparisons were used to assess binge-like consumption of each drug group 
relative to its respective vehicle during the first hour of testing in order to better capture the 
short-lived effect of the compound.   
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Additionally, separate univariate ANOVAs used dose of SB (0.0 or 6.0 µg) to analyze the 
time spent in the open area, the number of entries into the open area, time spent exploring the 
open area, and frequency of exploratory behavior in the elevated plus maze paradigm. Similarly, 
separate repeated-measures ANOVAs were used to assess behavior in the open-field locomotor 
tests with dose of SB (0.0 or 6.0 µg) as a between-subjects variable and total distance traveled, 
percent distance traveled in the center, and percent time spent in the center across the twelve 5-
min bins assessed as within-subject variables.  Tukey’s LSD post-hoc tests and Bonferroni 
corrections were employed throughout the analyses when applicable.   
Results 
 Repeated measures ANOVA revealed that binge-like ethanol drinking did not change 
over the course of the two hour test period (Figure 4.2A; Main effect of Time:  F(1,13) = 2.077, p 
= 0.173).  Although there was no main effect of dose (F(1,13) = 2.242, p = 0.158), there was a 
trend for drinking levels to change over time as a function of treatment, but this effect did not 
reach significance (Time×Dose Interaction:  F(1,13) = 2.334, p = 0.056); however, planned 
comparisons at the first hour of testing revealed that intra-CeA treatment with SB significantly 
reduced drinking levels relative to vehicle-treated controls (planned comparison:  (t(14) = 2.961, p 
= 0.010).  Similarly, our analyses did not reveal an effect of treatment on total drinking across 
the two hour test period (F(1,13) = 2.242, p = 0.158) nor did it impact BECs Figure 4.2B; F(1,11) = 
0.149, p = 0.707).    Importantly, whether the animal was treated with SB or vehicle first did not 
affect binge-like ethanol drinking (F(1,13) = 0.135, p = 0.719) or BECs (F(1,11) = 0.001, p = 0.982). 
 This effect was observed to be specific to ethanol as similar treatment did not alter hourly 
sucrose consumption (Main effect of time:  F(1,13) = 1.707, p = 0.214; Main effect of Dose:  F(1,13) 
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= 1.957, p = 0.185; Time×Dose Interaction:  F(1,13) = 0.547, p = 0.473; planned comparison at the 
first hour: t(14) = 2.035, p = 0.061) or total consumption across the two-hour test period (F(1,13) = 
1.957, p = 0.185; Figure 4.2C).  Moreover, drug order did not impact binge-like sucrose 
consumption (F(1,13) = 0.503, p = 0.491). 
 Not only was this effect reinforcer-specific, our analyses also revealed this effect to be 
specific to the CeA as intra-BLA infusion of SB did not affect binge-like ethanol drinking 
(Figure 4.2D; Main effect of Dose:  F(1,11) = 0.088, p = 0.772; Time×Dose Interaction:  F(1,11) = 
0.002, p = 0.962; planned comparison at the first hour: t(12) = 0.134, p = 0.896)- although there 
was a significant effect that indicated that animals drank significantly more ethanol during the 
second hour of testing relative to the first regardless of drug treatment (Main effect of Time:  
F(1,1) = 7.522, p = 0.019).  Moreover, there was no significant effect of SB across the total two 
hour test period (F(1,11) = 0.088, p = 0.772) nor was there an effect on BECs (Figure 4.2E; F(1,11) 
= 0.795, p = 0.392).  The order in which the animals received the drug did not alter drinking 
behavior (F(1,11) = 0.045, p = 0.836) or BECs (F(1,11) = 0.503, p = 0.493). 
 With the OX2R antagonist, we did not observe any main effects of TCS to alter binge-
like ethanol drinking over time (Figure 4.3A; Main effect of Dose:  F(1,13) = 2.344, p = 0.150; 
Main effect of Time:  F(1,13) = 0.833, p = 0.378); however, we did observe a significant 
interaction effect (Time×Dose Interaction:  F(1,13) = 8.980, p = 0.010).  Interestingly, further 
probing revealed that this effect was driven by the fact that vehicle treated animals drank 
significantly more ethanol during the second hour of testing relative to the first hour (t(14) = -
3.076, p = 0.008).  Further probing of this effect indicated that vehicle treated animals consumed 
significantly more ethanol relative to TCS treated animals during the second hour of testing (t(14) 
= 3.190, p = 0.007).  Notably, no difference was observed between the two treatment groups 
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during the first hour of testing (t(14) = -1.284, p = 0.220).  No effect was observed across the total 
two hour test period (F(1,13) = 2.330, p = 0.151) nor was there an effect on BECs (Figure 4.3B; 
F(1,13) = 0.631, p = 0.445).  Treatment order did not affect ethanol drinking (F(1,13) = 150, p = 
0.705) or BECs (F(1,13) = 4.148, p = 0.069). 
 To fully characterize the role of OX2Rs in the CeA, we also investigated the effects of 
direct infusions of TCS on binge-like sucrose consumption as well.  Our omnibus analyses 
yielded no significant effect of intra-CeA infusion of TCS on any measure (Figure 4.3C; Main 
effect of Time:  F(1,12) = 0.046, p = 0.834; Main effect of Dose:  F(1,12) = 0.462, p = 0.510; 
Time×Dose Interaction:  F(1,12) = 0.872, p = 0.369; planned comparison at the first hour: t(13) = -
0.709, p = 0.491; total drinking across the full two hours:  F(1,12) = 0.462, p = 0.510; drug order:  
F(1,12) = 0.277, p = 0.608). 
 What is more, the effect of inhibiting OX1Rs within the CeA was found not likely to be 
secondary to relief from a stressful state.  Specifically, intra-CeA treatment with SB did not 
significantly alter the amount of time the animal spent in the open area of the elevated zero maze 
(Figure 4.4A; F(1,13) = 0.230, p = 0.639) or the number of entries into the open area (Figure 4.4B; 
F(1,13) = 0.007, p = 0.933).  Moreover, such treatment did not affect the number of instances 
(Figure 4.4D; F(1,13) = 0.738, p = 0.406) or time (F(1,13) = 0.166, p = 0.690) spent exploring the 
open area. 
 Similar treatment with SB did not alter the proportion of distance traveled in the center of 
the chamber (Figure 4.5A; Main effect of Time:  F(11,132) = 1.484, p = 0.145; Main effect of 
Dose:  F(1,12) = 0.049, p = 0.828; Time×Dose Interaction:  F(11,132) = 0.453, p = 0.928) or 
proportion of time spent in the center (Figure 4.5B; Main effect of Time:  F(11,132) = 0.872, p = 
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0.454; Main effect of Dose:  F(1,12) = 0.030, p = 0.866; Time×Dose Interaction:  F(11,132) = 0.643, 
p = 0.573).  Importantly, inhibition of OX1Rs within the CeA did not significantly impact 
general locomotor activity (Figure 4.5C; Main effect of Dose:  F(1,12) = 1.040, p = 0.328; 
Time×Dose Interaction:  F(11,132) = 1.236, p = 0.270).  There was, however, a significant effect of 
time (Main effect of Time:  F(11,132) = 73.347, p < 0.001).  Further probing of this effect with 
Tukey’s LSD indicated that the animals tended to display greater activity towards the beginning 
of the test with the significant differences at the following time points:  5 min > all other time 
points (p’s < 0.001), 10 min > all subsequent time points (p’s < 0.001), 15 min > all subsequent 
time points after 20 min (p’s ≤ 0.002), 20 min > 40 min (p = 0.003), 35 min > 60 min (p = 
0.002). 
Discussion 
 The previous chapter identified the VTA as a brain region receiving OX input that helps 
regulate binge-like ethanol drinking behavior.  Results from the current chapter expand upon 
these findings by implicating the CeA as a target of OX input that modulates binge-like ethanol 
consumption as well.  Through our series of experiments, we demonstrated that OX1R- and 
possibly OX2R- signaling within the CeA selectively reduced binge-like ethanol, but not 
sucrose, intake.  Moreover, such an effect was specific to the CeA as intra-BLA infusion of the 
OX1R antagonist, SB, did not attenuate binge-like ethanol drinking.  Interestingly, we 
demonstrated that local inhibition of OX1R signaling in the CeA did not alter anxiety-like 
behavior as measured by the elevated zero maze and open-field locomotor test.  These effects 
were not due to alterations in sleep and arousal as intra-CeA infusion of SB did not affect general 
locomotor activity.  Together, these findings suggest that OXR signaling within the CeA 
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participates in modulating binge-like ethanol drinking independent of OX circuitry involved in 
stress responding. 
 The data from the current experiments provides convincing support that the OX1Rs 
within the CeA contribute to binge-like ethanol drinking.  Additionally, our findings suggest that 
OX2Rs may participate in this behavior as well.  Although we observed that TCS treated animals 
consumed less ethanol relative to vehicle treated animals during the second hour of our ethanol 
DID test (Figure 4.3A), one should interpret these effects cautiously.  Indeed, we also observed 
an odd effect that vehicle treated animals displayed elevated ethanol consumption during the 
second hour of testing relative to the first.  Thus, treatment with TCS may not have reduced 
binge-like drinking behavior, per se, but rather blocked an increase in drinking behavior that 
occurred during the second hour of testing.  Notably, we did not assess OX2R inhibition in the 
BLA nor did we explore anxiety-like behavior following infusion of TCS as the effects of the 
OX2R on binge-like ethanol drinking were less conclusive than those regarding the OX1R.  
Together with our findings from the previous chapter, these data prompt for a more 
thorough examination of the subtle nuances of OX2R signaling in binge drinking behavior.  For 
example, such an investigation could infuse a virus packaged with small interfering RNA 
(siRNA) that disrupts the production of the OX2R directly into the CeA.  If OX2Rs within the 
CeA play a significant role in binge drinking then one would predict that knockdown of the 
OX2Rs would cause the animal not to engage in binge-like ethanol drinking in a DID model.   
Taking this concept a step further, one could use a similar siRNA strategy to knockdown the 
OX1R while using a separate virus to overexpress the OX2R.  In this case, elimination of the 
OX1R would cause a reduction in binge-like ethanol drinking; however, if the OX2R contributes 
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to binge-like ethanol drinking then overexpressing the OX2R would rescue this phenotype such 
that the animal would once again engage in binge drinking. 
 Additionally, we observed that infusion of OXR antagonists within the CeA attenuated 
binge-like ethanol drinking but did not affect sucrose consumption.  This is rather surprising as 
multiple sources have demonstrated that peripheral OXR antagonists disrupt binge-like ethanol 
consumption as well as that of caloric (sucrose) and non-caloric (saccharin) reinforcers (Alcaraz-
Iborra et al, 2014; Anderson et al, 2014; Olney et al, 2015), which indicates that the OX system 
is involved in regulating responding to general, salient reinforcers whether it be ethanol or 
natural rewards (e.g. sucrose).  However, findings from the current and previous chapters as well 
as other studies (Schneider et al, 2007; Srinivasan et al, 2012) have reported that OX signaling 
within specific brain regions does not participate in responding to natural reinforcers.  In fact, 
Barson and colleagues (2014) discovered that distinct anatomical subregions within the same 
structure may be differentially involved in the consumption of ethanol versus that of a natural 
reward.  In that study, the authors demonstrated that orexin-A infused directly into the anterior 
portion of the paraventricular nucleus of the thalamus (PVT) augmented ethanol, but not sucrose, 
drinking; however, similar infusion of the peptide into the posterior PVT elevated sucrose, but 
not ethanol, intake.  As a whole, these findings support the idea that the OX circuitry that 
regulates ethanol responding may be largely independent of that which controls responding to 
natural rewards. 
 As with the findings from our VTA studies in the previous chapter, we did not observe 
any alterations in anxiety-like behavior following inhibition of OX1R signaling within the CeA 
as measured by the elevated plus maze and the open-field locomotor chamber, which indicates 
that OX signaling within the CeA does not modulate binge-like ethanol drinking by altering 
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stress responding.  Interestingly these data suggest that inhibiting OX1R signaling in this region 
depresses reward processing, however, additional tests such as operant tasks are required before 
any definitive conclusions can be drawn. 
The results from current chapter, to the best of our knowledge, provide the first evidence 
that OX signaling within the CeA modulates ethanol drinking behavior.   Further, these data 
indicate that this circuit (1) does not include the BLA, (2) does not regulate consumption of 
natural rewards, and (3) does not engage stress-related circuitry.  Together, these findings further 
establish the OX system as an attractive target for treating alcohol use disorders. 
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Figure 4.1:  Cannula placements for the studies that examined pharmacological inhibition of 
OX1Rs in the CeA via SB on binge-like ethanol and sucrose consumption as well as for the tests 
measuring anxiety-like behaviors (A), inhibition of OX2Rs in the CeA via TCS on binge-like 
ethanol and sucrose consumption (B), and the site-control study that infused SB into the BLA 
(C).  Following histological assessment of cannula placement, it was determined that four 
subjects from the SB-CeA studies, two from the TCS-VTA studies, and two from the SB-BLA 
studies were needed to be excluded due to poor cannula placement.  Each filled circle represents 
the location of a cannula in the target region. 
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Figure 4.2:  Inhibition of OX1Rs in the CeA selectively reduces binge-like ethanol consumption.  
Animals infused with SB directly into the CeA exhibited blunted binge-like ethanol consumption 
relative to vehicle-treated controls but only during the first hour of testing (A).  Despite this 
reduction in consumption, no significant effect was observed in BECs as measured at the end of 
the two hour test period (B).  Interestingly, intra-CeA infusion of SB did not significantly affect 
binge-like sucrose consumption at any point during the test (C).   Importantly, this phenomenon 
was specific to the CeA treatment as local infusion of SB into the BLA did not significantly 
impact binge-like ethanol drinking (D)- although animals did drink significantly more ethanol 
during the second hour of testing relative to the first, regardless of treatment condition.  
Moreover, intra-BLA SB did not affect subsequent BECs (E) at the end of the two hour test 
period.  Data presented as mean ± SEM.  * denotes that p < 0.05 relative to vehicle-treated 
animals during the first hour of testing.  # denotes that animals drank significantly more during 
the second hour of testing relative to the first hour regardless of treatment group.  Dotted line in 
(B) delineates 80 mg/dl, the minimum BEC to constitute a binge episode.  Data presented as 
Mean ± SEM. 
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Figure 4.3:  Inhibition of CeA OX2Rs impacts binge-like consumption.  Vehicle treated animals 
displayed an enhancement in binge-like ethanol drinking during the second hour of testing 
relative to the first (A) and infusion of TCS into the CeA blocked this behavior.  However, no 
changes in BECs were observed as a function of treatment with TCS (B) nor did it impact binge-
like sucrose intake (C).   Data presented as mean ± SEM.  * denotes that p < 0.05 relative to 
vehicle treated animals during the first hour of testing.  † signifies that p < 0.05 relative to TCS 
treated animals at the same time point. Dotted line in (B) delineates 80 mg/dl.  Data presented as 
Mean ± SEM. 
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Figure 4.4:  The effect on intra-CeA infusion of SB on anxiety-like behavior as measured via the 
elevated plus maze.  Relative to treatment with vehicle, inhibition of OX1Rs within the VTA 
does not significantly alter time spent in the open area (A), the number of entries into the open 
area (B), or the number and duration of exploration behaviors (C; left and right axes, 
respectively).  Data presented as Mean ± SEM. 
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Figure 4.5:  Inhibition of OX1Rs within the CeA via site-directed infusion of SB does not alter 
behavioral measures using the open-field locomotor assay.  Relative to treatment with vehicle, 
suppression of activity onto the OX1R within the VTA does not affect measures of anxiety-like 
behavior:  percent distance traveled in the center of the chamber (A) or the percent time spent in 
the center (B).  Additionally, relative to vehicle treated controls, animals infused with SB do not 
display detriments in locomotor behavior (C).  Data presented as Mean ± SEM. 
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CHAPTER 5 
GENERAL DISCUSSION 
Studies thus far investigating the role of the orexin (OX) system in ethanol drinking have 
largely used paradigms that promote only moderate levels of consumption.  Unlike other 
methods, animals in the “drinking in the dark” (DID) model consume large quantities of ethanol 
in a short period of time and display behavioral signs of intoxication (Rhodes et al, 2007).  Most 
notably, however, is the fact that binge-like ethanol drinking using the DID model has been 
demonstrated to differentially recruit neurobiological systems relative to other models of ethanol 
exposure.  For example, data from our lab has shown that compounds that act on neuropeptide Y 
(Sparrow et al, 2012) or corticotropin releasing factor (Lowery-Gionta et al, 2012; Sparta et al, 
2008) are effective at modulating excessive ethanol consumption in a DID model but have no 
significant impact in moderate levels of consumption.  
These findings highlight the necessity to investigate of the OX system in binge-like 
ethanol consumption.  Thus, the overarching goal of the present dissertation was to provide a 
detailed characterization of the role of the central OX system in binge-like ethanol drinking 
behavior.  Using the DID procedure to model binge-like ethanol consumption, findings from the 
present series of experiments confirmed that, like moderate levels of ethanol consumption, 
binge-like ethanol consumption engages the OX system in a manner that increases release of 
hypothalamic OX peptide.  Additionally, we went on to show that correcting this increase in OX 
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signaling within the ventral tegmental area (VTA) and central nucleus of the amygdala (CeA) via 
pharmacological intervention is sufficient to curtail binge-like ethanol drinking.  Interestingly, 
unlike peripheral administration of these same compounds, inhibiting OX1Rs in the VTA and 
CeA did not impact sucrose consumption.  Moreover, further investigation revealed that such 
treatments do not alter anxiety-like behavior in the animals, which suggests that the OX system 
likely modulates binge-like ethanol drinking via reward-related, rather than stress-related, 
mechanisms.  Together, these data extend the current literature by not only demonstrating that 
the OX system is significantly involved in binge-like ethanol drinking, but also provides a 
detailed characterization of the OX circuitry that contributes to this behavior.  
Summary of Experimental Findings 
Using immunohistochemical (IHC) analysis, we found that up to three cycles of binge-
like ethanol or sucrose drinking modulated orexin-A and -B immunoreactivity (IR) within the 
hypothalamus.  Interestingly, the pattern of effects for each OX peptide was not identical.  
Indeed, animals that experienced either one- or three-cycles of binge-like ethanol drinking 
displayed significantly lower orexin-A IR in the lateral hypothalamus (LH), but not perifornical 
area of the hypothalamus (PFA).  Moreover, this effect was not specific to ethanol as similar 
binge-like consumption of sucrose produced an identical pattern of effects.  On the other hand, 
we observed that orexin-B levels were only perturbed during the initial stages of binge-like 
drinking behavior as animals that experienced one cycle of DID exhibited a reduction in the 
number of orexin-B positive neurons.  However, these levels rebounded back to baseline after 
three cycles of DID.  What is more, these effects were not region-specific as both the LH and 
PFA showed a similar pattern of effects.  These data indicate that orexin-A originating within the 
LH is repeatedly recruited during binge-like ethanol drinking whereas orexin-B across the entire 
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hypothalamic OX field participates with initial, but not repeated, exposure to binge-like ethanol.  
Although we observed a reduction in OX peptide IR, we suspect that this reduction actually 
reflects an increase, rather than a decrease, in OX signaling.  Indeed, studies using in situ 
hybridization (Lawrence et al, 2006) and polymerase chain reaction (PCR; Barson et al, 2014) 
have reported increases in OX mRNA expression in rats that drank ethanol.  What is more, we 
and others have demonstrated that blocking signaling onto orexin receptors (OXRs) via 
administration of a systemic OX antagonist is capable of disrupting binge-like ethanol drinking 
behavior (Anderson et al, 2014; Olney et al, 2015), which supports the idea that this behavior, at 
least in part, is dependent on OX signaling.  In accordance with these findings, we hypothesize 
that the reduced levels of orexin-A and -B are a result of depleted OX levels following release 
from the cell. 
In an effort to better characterize the impact of binge-like ethanol drinking on the OX 
system, we next sought to measure OX mRNA following repeated cycles of DID using PCR 
analysis.  Contrary to the previous studies that found alterations in mRNA expression of the 
precursor, prepro-orexin, in response to ethanol exposure (Barson et al, 2015; Lawrence et al, 
2006; Morganstern et al, 2010), we found that binge-like ethanol drinking did not impact 
hypothalamic prepro-orexin expression- nor did we observe any changes in OX1R or OX2R in 
the hypothalamus, ventral tegmental area (VTA), or amygdala.  These results, however, did 
provide insight as to the nature of the changes we observed in our IHC analysis.  Specifically, we 
proposed that our reduced OX peptide IR levels reflected an increase in signaling.  Had 
expression of prepro-orexin mRNA decreased following DID a more parsimonious explanation 
would have been that the OX system is downregulated following binge-like ethanol drinking- as 
a result, both mRNA expression and peptide IR would have dropped following DID.  However, 
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the fact that prepro-orexin mRNA did not change indicates that the OX system is not 
downregulated following binge-like ethanol consumption, and combined with reduced stores of 
OX protein in neurons, our results are consistent with the idea that binge-like ethanol drinking is 
associated with increased OX release. 
These data- together with the previous findings that an OXR antagonist reduces binge-
like ethanol drinking (Anderson et al, 2014; Olney et al, 2015)- indicates that binge-like ethanol 
drinking involves the release of hypothalamic OX and that disrupting this signaling attenuates 
this behavior.  However, these data were unable to identify the specific targets of OX signaling 
that govern this effect.  Thus, the next two chapters sought to characterize the OX circuitry 
involved in modulating binge-like ethanol drinking behavior by using either an OX1R or OX2R 
antagonist administered directly into the VTA or central nucleus of the amygdala (CeA). 
Within the VTA, we found that inhibiting signaling onto the OX1R using SB-33487 
(SB), an antagonist selective for OX1Rs, caused a significant reduction in binge-like ethanol 
drinking relative vehicle-treated controls.  Furthermore, similar treatment using TCS-OX2-29 
(TCS), an antagonist selective for OX2Rs, did not significantly impact binge-like ethanol 
drinking, which suggests that this behavior is predominately regulated by the OX1R.   
Interestingly, we observed that this effect was specific to ethanol as SB had no significant effect 
on binge-like sucrose consumption, which suggests that a specific OX circuit modulates binge-
like ethanol drinking that does not participate in similar sucrose consumption.  Additionally, this 
effect was specific to the VTA as similar treatment with SB directly dorsal to the VTA did not 
affect subsequent binge-like ethanol drinking behavior.  Moreover, in an effort to identify the 
psychological process mediating this effect, we found that intra-VTA inhibition of OX1Rs did 
not alter anxiety-like behavior as measured by open-field locomotor tests as well as the elevated 
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zero maze.  This suggests that OX1R inhibition in the VTA does not reduce binge-like ethanol 
drinking by altering anxiety-like behaviors in the mouse (i.e. negative reinforcement) and 
presents the possibility that it does so by dampening the positive reinforcing properties of 
ethanol. 
Like the VTA, a similar pattern of effects was observed in the CeA.  Intra-CeA infusion 
of SB significantly reduced binge-like ethanol consumption during the first hour of testing but 
did not alter binge-like sucrose intake.  This effect was specific to the CeA as similar treatment 
targeting the basolateral amygdala did not significantly affect binge-like ethanol drinking.  The 
role of the OX2R in the CeA was relatively less clear as we did not observe any significant 
effects of TCS during the first hour of DID testing- although vehicle-treated animals exhibited 
elevated drinking levels during the second hour of testing that was not observed in TCS-treated 
animals.  Additionally, inhibiting OX2Rs in the CeA did not alter binge-like sucrose 
consumption.  What is more, blocking OX1Rs in the CeA- a region known to be involved in both 
positive reward (Kokkinidis and Borowski, 1991) and negative emotion (Gilpin and Roberto, 
2012; Koob, 2008)- was found not to alter anxiety-like behavior, which indicates that binge-like 
ethanol drinking does not involve stress-related OX circuitry within the CeA and suggests it 
engages OX reward-circuitry in this region. 
Orexin Circuitry Involved in Binge-Like Ethanol Drinking 
The overarching goal of the current dissertation was to provide a detailed characterization 
of the OX circuitry that governs binge-like ethanol consumption using a variety of behavioral, 
molecular, and pharmacological techniques.  Fortunately, such investigations are relatively 
simplified compared to other peptide systems as OX is exclusively synthesized in the 
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hypothalamus; thus, the origin of OX in any given circuit will be restricted to the hypothalamus.  
Our investigations of OX peptide IR and prepro-orexin mRNA expression suggest that binge-like 
ethanol drinking resulted in increased OX signaling.  What is more, our immunohistochemistry 
(IHC) data suggest that the OX circuits recruited by binge-like ethanol drinking originate 
specifically from the lateral hypothalamus (LH).  Specifically, we observed signs of increased 
release of orexin-A from neurons located within the LH, but not perifornical area of the 
hypothalamus (PFA).  Although we observed similar signs of activation of orexin-B within both 
the LH and PFA, the fact that orexin-B has a very low affinity for the OX1R coupled with the 
fact that our pharmacological studies revealed binge-like ethanol drinking is predominately 
modulated through the OX1R suggests that orexin-B likely does not significantly contribute to 
this behavior.  Thus, orexin-A, originating from the LH, is the most likely source of OX that 
contributes to binge-like ethanol drinking.  These IHC studies, however, were unable to 
determine the projection sites of the terminals releasing OX.  By using site-directed 
pharmacology, we were able to identify two separate OX pathways that modulate binge-like 
ethanol drinking:  the LHVTA and LHCeA circuits. 
Srinivasan and colleagues (2012) have previously implicated the VTA as modulating 
ethanol responding in an operant paradigm.  However, this study used a nonselective, dual orexin 
receptor antagonist that targets both OXRs and was unable to characterize this circuit at the level 
of the receptor.  However, by using compounds selective for either the OX1R or OX2R, our site-
directed pharmacology studies were able to isolate and examine the contribution of individual 
OXRs in specific brain regions.  Our first investigation of OX circuitry revealed that the VTA is 
involved in binge-like ethanol drinking behavior.  What is more, we were able to extend upon the 
findings of Srinivasan and colleagues (2012) by demonstrated that the OX1R, but not OX2R, 
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specifically regulates this behavior in the VTA.  Additionally, we also identified the CeA as an 
important target of OX input that modulates binge-like ethanol drinking.  As with the VTA, we 
found that the OX1R is the primary receptor subtype in the LHCeA circuit that guides this 
behavior- although our data was unable to completely rule out the OX2R as making significant 
contributions as well.  Importantly, the data collected from these experiments- to our knowledge- 
provide the first evidence that OX signaling within the CeA contributes to ethanol drinking 
behavior.  Figure 5.1 provides an illustration of the OX pathways involved in binge-like ethanol 
drinking that our series of experiments has revealed as well as other structures that have 
previously been demonstrated to be involved in ethanol drinking or responding to natural 
rewards.  It is worth noting that other brain areas have previously been implicated in modulating 
either ethanol drinking or natural reinforcers (Castro et al, 2016; Ho and Berridge, 2013; Kay et 
al, 2014).  However, those reports examined OX signaling in modulating either ethanol or 
natural reinforcers in isolation and did not determine the specificity of the effect; thus, those 
regions were not included in the present diagram. 
Reward- Versus Stress-Related Orexin Circuitry in Alcohol Drinking 
 Alcohol abuse is a complex human behavior that is comprised of a multitude of factors 
that contribute to the likelihood that an individual will consume alcohol.  Two of the broader, 
overarching psychological components of alcohol use and abuse are the positive-reinforcing and 
negative-reinforcing properties of the drug (Eckardt et al, 1998; Gilpin and Koob, 2008; Koob, 
2009; Sinha, 2007).  Indeed, ethanol activates the mesolimbic dopaminergic pathway in both 
animals (Di Chiara and Imperato, 1988; Gessa et al, 1985) and humans (Gilman et al, 2012; 
Ingvar et al, 1998).  What is more, stressful situations have been shown to lead to increased 
ethanol consumption in nonhuman primates (Barr et al, 2004; Higley et al, 1991); however, 
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ethanol has anxiolytic effects as it reduces anxiety-like behavior in rodents (Durcan and Lister, 
1988; Pandey et al, 2008; Prunell et al, 1994).  Thus, the anxiolytic effect of ethanol may help 
explain why individuals who rank negative-reinforcement among the key reasons they consume 
alcohol are more likely to drink more frequently and suffer from alcohol-related problems (Ray 
et al, 2009) as they are using ethanol to self-medicate a state of anxiety.   
With regard to our study, it is hypothesized that an OXR antagonist would ultimately 
reduce binge-like ethanol drinking because the animal is no longer motivated to seek out the 
anxiolytic effect of ethanol because inhibiting the OX system would suppress the stress response.  
In terms of negative reinforcement, any unpleasant stressful state that the animal could possibly 
experience would be relieved by the OXR antagonist, thereby negating the need for the 
consumption of ethanol.  However, our experiments involving the open-field locomotor 
chambers and elevated zero maze revealed that inhibiting OX1R signaling in the VTA and CeA 
did not alter anxiety-like behavior.  These findings provide valuable insights into the overarching 
psychological processes that help explain how manipulations in the OX produce changes in 
ethanol consumption.  Specifically, these data demonstrate that the OX-induced changes in 
binge-like ethanol drinking were not mediated by stress-related circuitry.  On the other hand, this 
presents the very strong possibility that reward-related OX circuits modulate binge-like ethanol 
drinking. 
The OX system most likely modulates the reinforcing properties of ethanol as OX has 
previously been shown to regulate dopaminergic activity in the mesolimbic reward system 
(España et al, 2010; Narita, 2006; Vittoz et al, 2008).  In fact, local infusions of orexin-A into 
the VTA induces conditioned place preference (CPP) in rats in a dopamine-dependent manner 
(Taslimi et al, 2012).  Furthermore, OX has been demonstrated to regulate the reinforcing effects 
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of numerous drugs of abuse including cocaine (España et al, 2010; Hollander et al, 2012), 
nicotine (Hollander et al, 2008; LeSage et al, 2010), morphine (Harris et al, 2005; Sharf et al, 
2010) as well as ethanol.  Indeed, Shoblock and colleagues (2011) demonstrated that systemic 
administration of an OX2R antagonist was capable of blocking ethanol-induced CPP.  Moreover, 
peripheral treatment with an OXR antagonist results in a marked reduction in breakpoints for 
ethanol responding in a progressive ratio schedule of reinforcement (Anderson et al, 2014; Jupp 
et al, 2011a).  Although our experiments did not directly test whether our treatments modulated 
the reinforcing properties of ethanol, these data provide substantial support for the idea that OX 
modulates ethanol drinking by impairing the positive-reinforcing effects of ethanol.  In terms of 
the present dissertation, suppressing OX signaling in the LHVTA or LHCeA circuits 
disrupts binge-like ethanol drinking by dampening the reinforcing properties of ethanol.  By 
blunting the reinforcing effects of ethanol, the animal exhibits reduced motivation to consume 
this drug. 
It is worth noting that although we observed that our manipulations did not alter anxiety-
like behavior, this does not prove that stress-related OX circuitry is not involved in alcohol 
drinking.  In fact, Richards and colleagues (2008) showed that SB was able to block yohimbine-
induced ethanol-seeking behavior.  This suggests that OX may participate in stress-related 
relapse as yohimbine is thought to induce a stress-like state (Vythilingam et al, 2000) and 
activates stress-related systems in a similar pattern to footshock-induced stress (Funk et al, 
2006).  In humans, abstinent alcoholics have been reported to have lower levels of orexin-A 
mRNA relative to individuals experiencing acute withdrawal from alcohol (Bayerlein et al, 
2011).  Other reports have found circulating OX levels to be positively correlated with severity 
of withdrawal symptoms following acute alcohol withdrawal (von der Goltz et al, 2011).  More 
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recently, it has also been observed that peripheral treatment with an OX1R antagonist disrupts 
ethanol consumption in ethanol-dependent mice following chronic intermittent ethanol (CIE) 
vapor exposure (Lopez et al, 2016).  Importantly, similar models using ethanol vapor have been 
shown to enhance anxiety-like behavior (Kliethermes et al, 2004), which may, in part, promote 
subsequent increases in ethanol consumption these models produce (Becker and Lopez, 2004; 
Finn et al, 2007; Funk et al, 2007; Gilpin et al, 2011; Lopez et al, 2011).  Importantly, our lab 
has shown that up to 10, 4-day cycles of DID ethanol access does not produce alterations in 
anxiety-like behavior (Cox et al, 2013); thus, the DID model used in the current dissertation may 
not have been the optimal model to study the participation of stress-related OX circuitry in 
excessive ethanol consumption.  Nonetheless, these reports indicate that the OX system clearly 
communicates with the stress system and that stress-related OX circuitry is capable of 
modulating responding to ethanol; therefore, the contributions of stress-related OX circuitry in 
AUDs cannot be discounted based on the results from the present dissertation alone. 
Specific Orexin Circuits are Selective for Ethanol 
 Over eons of evolution, the brain’s reward circuitry has become a highly efficient and 
highly adaptive neurobiological instrument that encourages behavior necessary for the survival 
of a species including drinking, feeding, and sexual behavior, among others.  A complex 
collection of brain structures work in concert in order for an organism to find a behavior 
reinforcing, motivate it to engage in that behavior, and create a memory of the event so it may 
seek out and/or engage the behavior in the future.  It is believed that the addictive properties of 
drugs of abuse manifest themselves by potently activating these brain areas (e.g. hypothalamus, 
VTA, amygdala, hippocampus, nucleus accumbens (NAc), etc.) and “hijacking” the existing 
reward circuitry in such a way that the organism is preoccupied with seeking out and taking the 
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drug.  In this view, there is a very large degree of overlap between the neurocircuitry recruited by 
drugs of abuse, such as ethanol, and that which regulates responding to natural rewards, such as 
sucrose (Thiele et al, 2003; Volkow et al, 2013). 
It is for this reason that perhaps the most exciting finding from the current set of 
experiments has to do with the specificity of these LHVTA and LHCeA OX circuits- 
specifically that these circuits were demonstrated to regulate binge-like ethanol drinking, yet did 
not contribute to binge-like sucrose consumption.  Previously, we and others have shown that a 
systemic injection of an OXR antagonist reduces binge-like consumption of ethanol as well as 
other natural reinforcers including sucrose and the non-caloric sweetener, saccharin (Alcaraz-
Iborra et al, 2014; Anderson et al, 2014; Olney et al, 2015).  Even data from our IHC analysis 
revealed that OX was released following binge-like sucrose drinking in addition to ethanol.  
Taken alone, these data indicate that the OX system regulates the overarching hedonic properties 
shared by salient reinforcers in general and seem to confirm the hypothesis that the OX system is 
recruited by ethanol because this drug “hijacks” those systems that regulate responding to natural 
rewards.   
However, a growing number of studies have emerged that report that pharmacological 
disruption of OX signaling effects ethanol responding yet leaves responding to sucrose intact.  
Indeed, early investigations reported that systemic (Jupp et al, 2011a) as well as intra-VTA 
(Srinivasan et al, 2012) administration of an OXR antagonist reduces operant responding to 
ethanol, but not sucrose.  More recently, it has also been demonstrated that infusion of orexin-A 
into the anterior paraventricular nucleus of the thalamus augments ethanol drinking but does not 
alter sucrose drinking (Barson et al, 2015).  A similar pattern has also been observed in other 
natural rewards as infusion of orexin-A into the paraventricular nucleus of the hypothalamus or 
95 
 
LH enhances ethanol drinking but does not produce any effects in food consumption or water 
drinking (Schneider et al, 2007).  Additionally, our present results revealed that inhibiting 
OX1Rs in the VTA and CeA disrupt binge-like ethanol drinking without affecting binge-like 
sucrose consumption.  To be clear, this collection of findings does not invalidate the conclusion 
that the OX system modulates responses to general, salient reinforcers.  They do, however, 
indicate that the specific OX pathways that regulate binge-like ethanol drinking may be largely 
independent of those that modulate responding to a natural reward. 
However, one may argue that we and others did not observe alterations in sucrose 
consumption because the concentration of sucrose was too low to be adequately reinforcing to 
the animal, thus the OXR antagonist was not effective in disrupting sucrose responding.  Indeed, 
we used a relatively low concentration of sucrose (3%) in our studies and others have used even 
lower concentrations (below 1%; Brown et al, 2015; Jupp et al, 2011) while studies that 
demonstrated an OX-dependent reduction in sucrose consumption used a considerably higher 
concentration (10%; Alcaraz-Iborra et al, 2014).  The different concentrations of sucrose likely 
have different reinforcing values.  That is, an animal would likely be more motivated to consume 
a greater concentration of sucrose (with a higher reinforcement value) relative to a lower 
concentration (with a lower reinforcement value).  Therefore, a procedure that uses a greater 
concentration of sucrose may be more sensitive in detecting an effect on sucrose consumption.  
Nonetheless, other reports have used relatively higher concentrations of sucrose (5%) and 
observed specificity to ethanol responding (Srinivasan et al, 2012) while very low concentrations 
(1%) have been used in which OXR antagonists have successfully disrupted both ethanol and 
sucrose consumption (Anderson et al, 2014).  Thus, the concentration of sucrose- and the 
reinforcing value of the stimulus- is not likely a confounding factor in these investigations. 
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 As it currently stands, several studies have reported that system-wide manipulations of 
the OX system modulates responding to sucrose and/or saccharin (Alcaraz-Iborra et al, 2014; 
Anderson et al, 2014; Matsuo et al, 2011; Olney et al, 2015).  These observations clearly 
indicate that OX pathways exist that participate in regulating the intake of natural rewards- yet a 
number of studies, including the current dissertation, exist that demonstrate that OX agents 
delivered directly into specific brain regions are able to selectively modulate responding to 
ethanol while leaving responding to natural rewards intact (Brown et al, 2015; Jupp et al, 2011a; 
Morganstern et al, 2010; Schneider et al, 2007; Srinivasan et al, 2012).  As a whole, these data 
raise the question:  If specific OX circuits, such as the LHVTA and LHCeA, selectively 
modulate responding to ethanol then which OX pathways regulate responding to a natural 
reward? 
 Relatively few reports exist that document that signaling within a specific brain region 
modulates responding to a natural reward without affecting ethanol responding.  In one such 
example, Schneider and colleagues (2007) showed that infusing orexin-A directly into the shell 
of the NAc (NAcSh) enhanced feeding behavior- an effect that was absent when the rats were 
presented with ethanol.  This dissociation was arguably best documented in a recent report by 
Barson and colleagues (2014).  In this study, the researchers were able to promote ethanol 
drinking in the anterior, but not posterior, PVT following local infusion of OX peptide.  What is 
more, they found the opposite pattern results with sucrose consumption- specifically that the 
posterior, but not anterior, PVT regulates sucrose intake.  Furthermore, OX is thought to play a 
considerable role in hedonic alliesthesia, which refers to the pleasant or unpleasant perception of 
a stimulus depending on the internal state of the organism (see Berridge et al, 2010 for review).  
Indeed, OX signaling within the ventral pallidum (Ho and Berridge, 2013) and NAcSh (Castro et 
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al, 2016) have been shown to enhance the palatability of sucrose as measured using taste 
reactivity.  Similarly, orexin-A infused directly into the nucleus of the solitary tract- a region 
critically involved in processing gustatory information (Bradley et al, 1996; Norgren, 1983)- 
increased consumption of a high-fat diet while SB reduced consumption (Kay et al, 2014).  
Taken together, these data suggest that the OX system may employ distinct and independent 
pathways that modulate responding to ethanol and natural rewards- a quality that makes this 
peptide system an attractive target for treating AUDs. 
The Orexin System is a Promising Target for the Treatment of Alcohol Use Disorders 
 Over the past decade, alcohol researchers investigating the role of OX have uncovered a 
rather consistent relationship between the OX system and ethanol responding.  Indeed, OX 
agonists increase drinking (Barson et al, 2015; Schneider et al, 2007) while antagonists decrease 
intake (Anderson et al, 2014; Jupp et al, 2011a; Lawrence et al, 2006; Lopez et al, 2016; 
Moorman and Aston-Jones, 2009; Olney et al, 2015).  Inhibiting OXRs dampens the reinforcing 
properties of ethanol (Anderson et al, 2014; Jupp et al, 2011a; Shoblock et al, 2011).  
Reinstatement of ethanol seeking behavior activates OX neurons (Dayas et al, 2008; Jupp et al, 
2011b; Millan et al, 2010).  Likewise, OX antagonists disrupts ethanol- (Martin-Fardon and 
Weiss, 2012), cue- (Brown et al, 2015), and yohimbine-induced reinstatement of ethanol seeking 
behavior (Richards et al, 2008).  In humans, OX levels are positively correlated with the severity 
of withdrawal symptoms in alcoholics (Bayerlein et al, 2011; von der Goltz et al, 2011).  As a 
whole, these findings corroborate the notion that ethanol responding parallels OX signaling.  
Thus, pharmacological agents that serve to suppress OX signaling should provide relief for 
individuals suffering from AUDs as it may help reduce consumption, avoid relapse, and allow 
for a less psychologically distressful period of withdrawal. 
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 Taken alone, the fact that OX may be able to ameliorate multiple aspects of alcohol use 
and abuse may be enough to warrant serious pursuit of OX antagonists as effective treatments for 
AUDs.  However, the major appeal of this peptide system in this regard comes from the fact that 
the circuitry that modulates ethanol responding may largely be separate from that which governs 
responding to natural rewards.  Indeed, results from the current dissertation as well as other 
studies (Barson et al, 2015; Jupp et al, 2011b; Lopez et al, 2016; Schneider et al, 2007; 
Srinivasan et al, 2012) suggest that the OX pathways for ethanol and natural rewards may not 
completely overlap.  It may be possible to exploit this fact in order to make pharmacological 
treatment options for alcoholics that specifically target alcohol responding without disrupting 
responding to natural rewards.  For example, one such FDA approved treatment for alcoholism is 
naltrexone, an opioid antagonist, which is well tolerated and generally considered a relatively 
safe treatment option (Donoghue et al, 2015; Fujioka, 2015; Oslin et al, 2015).  However, 
opioids play a critical role in modulating the perceived reinforcing value of palatable foods 
(Drewnowski et al, 1992; Peciña and Berridge, 2005).  In fact, it has been documented that 
treatment with naltrexone can lead to reduced activation of reward-related brain regions in 
response to chocolate (Murray et al, 2014) and severely blunted the self-reported hedonic 
properties of sucrose (Langleben et al, 2012).  Some individuals may find such a side effect 
undesirable and may be inclined to choose a treatment option without such secondary effects, 
such as an OXR antagonist. 
 Considering the wide array of neurobiological functions in which OX participates, it is 
important to consider adverse consequences of using OX antagonists to treat AUDs as well.  For 
example, preclinical models of depression have been associated with low OX levels in the VTA 
and prefrontal cortex (Nocjar et al, 2012).  In fact, this is a consequence commonly encountered 
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when suppressing other systems that facilitate activity in the reward circuit such as dopamine 
(DA), norepinephrine, and serotonin (see Ruhé et al, 2007 for review).  Clearly, this is 
problematic to those working to develop an OXR antagonist for the treatment for AUDs as this 
data suggests that suppressing endogenous OX function may lead to a negative affective state.   
However, it may be possible to correct a depressed affective state that OXR antagonists 
could possibly produce by controlling the relative levels of dynorphin.  Indeed, recent evidence 
indicates that OX and dynorphin are expressed in the same neurons and are even released in the 
same vesicles as cotransmitters in the VTA (Muschamp et al, 2014).  Moreover, results from 
their experiments suggest that OX modulates reward activity, in part, by counteracting the anti-
reward effects of dynorphin.  In this way, the ultimate experience of a positive (reward) or 
aversive (anti-reward) state may manifest, in part, due to the relative balance between OX and 
dynorphin signaling with relatively higher levels of OX producing a positive state while higher 
levels of dynorphin would result in a negative state.  Thus, using an OXR antagonist in 
combination with a compound that blocks kappa-opioid receptors (KOR)- the receptor that 
dynorphin binds to- may prove beneficial.  In fact, one of the few FDA-approved treatment 
options for AUDs is the opioid antagonist, naltrexone.  Although naltrexone predominately acts 
through the mu-opioid receptor, it has been shown to bind to KORs as well- albeit to a lesser 
degree (Ko et al, 1998; Wang et al, 2007).  Therefore, combining an OXR antagonist with 
naltrexone may serve to suppress signaling onto KORs in tandem with OXRs, which may be 
enough to balance the scales in relative signaling between the two systems and possibly reduce 
any depressive symptoms that may arise from using an OXR antagonist alone. 
In addition, arguably the most studied role of the OX system is in regulating sleep and 
arousal.  In fact, narcolepsy is associated with low levels of OX (Chemelli et al, 1999; Lin et al, 
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1999; Peyron et al, 1998; Willie et al, 2003) and the OX system is gaining a great deal of 
attention by sleep researchers as a target for the treatment of insomnia.  In the summer of 2014, 
the FDA approved the use of suvorexant (Belsomra®), a dual OX receptor antagonist developed 
by Merck, for the treatment of insomnia (Traynor, 2014).  Together, this information demands 
caution by alcohol researchers attempting to develop treatments for AUDs that target the OX 
system as the induction of somnolence would be an unwanted side effect for any individual 
attempting to maintain a normal lifestyle.   
 However, we have previously demonstrated that it is possible to achieve a dose of an 
OXR antagonist that is capable reducing ethanol intake that does not impair general locomotor 
activity (Olney et al, 2015).  Similarly, results from the current set of experiments confirm this 
finding by showing that the same dose of SB in the VTA and CeA that disrupts binge-like 
ethanol consumption did not impact locomotor activity.  Thus, it may be possible to use a dose of 
suvorexant that is low enough to protect against alcohol drinking yet does not induce somnolence 
in the individual.  Although this has yet to be examined using a model of ethanol intake, 
preliminary evidence suggests that suvorexant can attenuate the reinforcing properties of cocaine 
self-administration without altering general locomotor activity (Simmons et al, 2015).  Though 
promising, further research into the efficacy of suvorexant as a treatment for AUDs is required.  
Nonetheless, these data suggest that OXR antagonists- possibly in combination with KOR 
antagonists- may be capable of combating alcohol use and abuse in a variety of ways without 
adversely affecting responding to natural rewards or inducing somnolence- making the OX 
system a very attractive target for the treatment of AUDs. 
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Future Directions 
 A number of advancements to our collective knowledge of the role of the OX system in 
binge-like ethanol drinking were obtained through our current set of experiments; however, some 
of these results have opened the door for follow up investigations.  For example, our experiments 
revealed two separate OX pathways, the LHVTA and LHCeA circuits, which modulate 
binge-like ethanol consumption in the same direction.  Future studies may simultaneously 
suppress OX signaling within both of these circuits to determine if inhibiting multiple OX 
pathways further reduces- or even completely blocks- binge-like ethanol drinking.  This can be 
accomplished via bilaterally cannulation of each target region (i.e. the VTA and CeA); however, 
a less invasive technique may be to employ pharmacogenetics tools.  In this case, viral vectors 
containing designer receptors exclusively activated by designer drugs (DREADDs) can be 
infused directly into the VTA and CeA.  In this way, only a single peripheral dose of the 
DREADD activator, clozapine-N-oxide, is required to simultaneously inhibit OX signaling in the 
VTA and CeA.  These results may be particularly relevant to the potential efficacy of a 
systemically administered OXR antagonist used to treat AUDs as such a compound would likely 
affect multiple OX pathways. Moreover, our experiments that examined sucrose consumption 
used animals that were not ethanol naïve.  It is possible that experience with ethanol “usurped” 
the OX circuitry in such a way that it was no longer responsive to natural rewards.  Thus, future 
studies could be conducted using ethanol naïve mice in order to examine whether OX circuits 
that modulate ethanol and natural rewards are truly distinct or if OX circuits may undergo 
ethanol-induced changes that primes the circuit to modulate ethanol consumption over that of a 
natural reward.  Additionally, our sample size proved to be insufficient to adequately detect the 
presence of OX2Rs in the VTA and amygdala- clearly future studies will need to use more 
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animals than ten per group in order to properly assess changes in OX2Rs.  Also, our experiments 
revealed that the OX2R participates minimally- if at all- in binge-like ethanol drinking; however, 
it may be premature to conclude that this subtype does not make significant contributions to this 
behavior.  For example, the OX2R antagonists have specifically been shown to block ethanol-
induced CPP as well as ethanol self-administration and reinstatement (Shoblock et al, 2011), 
which suggests that OX2Rs do, indeed, participate in ethanol responding. Further investigations 
into the role of the OX2R are required before any definitive conclusions can be drawn.  As 
discussed in Chapter 4, viral-mediated knockdown of OX2R mRNA is a viable option for 
elucidating the role of OX2Rs in binge-like ethanol drinking.  Moreover, we cannot completely 
rule out the contribution of stress-related OX circuits in binge-like ethanol drinking.  Indeed, the 
DID model may not have been the ideal model to examine such an effect; thus, a different 
model, such as CIE vapor exposure, may be preferred.  For example, future studies may suppress 
OX function in specific brain regions (e.g. VTA or CeA) using pharmacogenetics techniques in 
animals undergoing CIE vapor exposure.  If stress-related OX circuitry is involved in excessive 
ethanol consumption then one would expect that such inhibition of OX function would reduce 
subsequent ethanol drinking and, importantly, anxiety-like behavior relative to mice whose OX 
system remained undisturbed throughout CIE vapor exposure.  Additionally, the ability for the 
OX system to modulate binge-like ethanol drinking by regulating the positive reinforcing effects 
of ethanol needs to be directly examined.  This can be accomplished by using fast-scan cyclic 
voltammetry (FSCV) to measure DA efflux onto the NAc during DID.  It would be predicted 
that inhibiting OX signaling within OX circuits such as the LHVTA or LHCeA pathways- 
in addition to reducing binge-like ethanol drinking- would decrease DA release in the NAc as 
measured by FSCV.  Perhaps the most exciting aim this line of research could pursue is the 
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effectiveness of suvorexant in treating AUDs, which can be accomplished rather easily using an 
animal model in which binge-like ethanol drinking is assessed following peripheral 
administration of suvorexant.  It would be expected that such treatment would reduce binge-like 
ethanol drinking- although, follow up investigations would be necessary to examine its effect on 
the state of arousal in the animal.  In humans, rather than moving directly to prescribing 
suvorexant for “off-label” disorders (i.e. alcohol use and abuse) a better approach may be to 
begin collecting self-reported alcohol use among patients with insomnia using suvorexant.  A 
pattern of reduced alcohol use in this case may serve as an impetus to pursue such treatment 
more aggressively.  Regardless of the direction that future studies may take, a better 
understanding of the role of the OX system in binge-like ethanol drinking behavior will greatly 
inform the current understanding of the neurobiology of alcohol use and abuse and may 
potentially reveal novel treatments for this self-destructive disorder. 
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Figure 5.1:  Circuit diagram illustrating the separate OX pathways that have been demonstrated 
to be involved in the selective modulation of ethanol responding or that of a natural reward.  
Here, OX neurons originating in the hypothalamus (blue region) project to various structures to 
modulate ethanol intake (orange regions) or natural rewards (green regions).  Moreover, results 
from the current experiments were able to provide a more detailed characterization of the 
LHCeA and LHVTA circuitry.  Within the CeA (bottom left inset), OX is released from 
presynaptic LH orexinergic projection neurons and acts on OX1Rs and possibly OX2Rs located 
on postsynaptic CeA neurons.  Within the VTA (bottom right inset), OX is similarly released 
from presynaptic LH orexinergic projection neurons and interacts with OX1Rs, but not OX2Rs, 
expressed on postsynaptic VTA neurons.  OX signaling within these circuits selectively 
modulates binge-like ethanol drinking but does not regulate sucrose consumption nor do they 
modulate anxiety-like behavior.  The ?’s around the OX2R in the CeA circuit (bottom left inset) 
indicates the uncertainty regarding the contribution of this receptor subtype in modulating binge-
like ethanol drinking.  The greyed out OX2R in the VTA circuit (bottom right inset) signifies 
that this receptor subtype does not participate in modulating binge-like ethanol drinking 
behavior.  CeA, central nucleus of the amygdala; LH, lateral hypothalamus; NAc, Nucleus 
Accumbens; OX, orexin; OX1R, orexin-1 receptor; OX2R, orexin-2 receptor; PL, paralimbic 
cortex; PVN, paraventricular nucleus of the hypothalamus; aPVT, anterior paraventricular 
nucleus of the thalamus; pPVT, posterior paraventricular nucleus of the thalamus; VTA, ventral 
tegmental area.  References for each brain region are as follows:  CeA, Chapter 4 of current 
dissertation; NAc, (Schneider et al, 2007); PL, (Brown et al, 2015); PVN, (Schneider et al, 
2007); PVT (Barson et al, 2015); VTA, (Srinivasan et al, 2012) and Chapter 3 of current 
dissertation. 
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